Next Article in Journal
Effects of Gut Metabolites and Microbiota in Healthy and Marginal Livers Submitted to Surgery
Next Article in Special Issue
A Novel Formulation of Glucose-Sparing Peritoneal Dialysis Solutions with l-Carnitine Improves Biocompatibility on Human Mesothelial Cells
Previous Article in Journal
Infections and Immunotherapy in Lung Cancer: A Bad Relationship?
Previous Article in Special Issue
Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 1
10.3390/ijms22010043
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

New Potential Biomarkers for Chronic Kidney Disease Management—A Review of the Literature

by
Irina Lousa
1,
Flávio Reis
2,3,4,
Idalina Beirão
5,6,
Rui Alves
7,8,
Luís Belo
1 and
Alice Santos-Silva
1,*
1
UCIBIO\REQUIMTE, Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
2
Institute of Pharmacology & Experimental Therapeutics, & Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
3
Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-504 Coimbra, Portugal
4
Clinical Academic Center of Coimbra (CACC), 3000-075 Coimbra, Portugal
5
Universitary Hospital Centre of Porto (CHUP), 4099-001 Porto, Portugal
6
Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal
7
Nephrology Department, Coimbra University Hospital Center, 3004-561 Coimbra, Portugal
8
University Clinic of Nephrology, Faculty of Medicine, University of Coimbra, 3000-075 Coimbra, Portugal
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(1), 43; https://doi.org/10.3390/ijms22010043
Submission received: 30 November 2020 / Revised: 14 December 2020 / Accepted: 21 December 2020 / Published: 22 December 2020
(This article belongs to the Special Issue Kidney Injury: From Molecular Basis to Therapies 3.0)
Browse Figures
Versions Notes

Abstract

:
The prevalence of chronic kidney disease (CKD) is increasing worldwide, and the mortality rate continues to be unacceptably high. The biomarkers currently used in clinical practice are considered relevant when there is already significant renal impairment compromising the early use of potentially successful therapeutic interventions. More sensitive and specific biomarkers to detect CKD earlier on and improve patients’ prognoses are an important unmet medical need. The aim of this review is to summarize the recent literature on new promising early CKD biomarkers of renal function, tubular lesions, endothelial dysfunction and inflammation, and on the auspicious findings from metabolomic studies in this field. Most of the studied biomarkers require further validation in large studies and in a broad range of populations in order to be implemented into routine CKD management. A panel of biomarkers, including earlier biomarkers of renal damage, seems to be a reasonable approach to be applied in clinical practice to allow earlier diagnosis and better disease characterization based on the underlying etiologic process.

1. Introduction

Chronic kidney disease (CKD) is a long-term condition characterized by a progressive and irreversibly loss of kidney function or persisting renal damage [1]. CKD has been recognized as a global public health problem. Estimation reports on prevalence, as well as on related morbidity and mortality, confirmed the high socioeconomic burden of this disease [2], particularly due to progression to end-stage renal disease (ESRD) and association with cardiovascular disease (CVD).
Irrespective of the etiology of CKD, various structural and functional changes within the kidney will develop during the disease course, resulting in glomerular, tubular and vascular injuries [3]. The progression phase of the disease is characterized by a persistent state of inflammation, hypoxia and oxidative stress that contribute to the development of renal fibrosis [4] (Figure 1).
In clinical practice, glomerular filtration rate (GFR) estimation and albuminuria are widely used for CKD diagnosis and prognosis. GFR estimation correlates with the degree of kidney dysfunction, while albuminuria identifies the presence of renal damage. However, these traditional biomarkers only increase when a significant filtration capacity has been lost and kidney damage is advanced [5]. Thus, they increase when several injuries have already occurred in renal cells [6,7]. Early identification of CKD is an important unmet medical need, not only to predict and prevent CKD progression, but also to further improve patients’ survival and reduce associated morbidities. Hence, more sensitive and early biomarkers are needed to achieve this goal.
Over the last twenty years, several new biomarkers were identified as promising candidates for CKD management. In this review, we selected some of the most well-studied and well-defined biomarkers, which are associated with different pathophysiological mechanisms underlying CKD initiation and progression. We summarize the more important results from published studies on selected biomarkers of renal function, tubular lesions, endothelial dysfunction, and inflammation. A section on novel metabolomic biomarkers is also included due to the increasing attention towards metabolomic analysis in this field. A search on PubMed of human studies published between 2015 and 2020 was conducted using the keywords “CKD”, “chronic kidney disease” and “chronic renal insufficiency”; the biomarker name (s) to search the title or abstract; or the MeSH term “Metabolomics”. From the retrieved articles, and after title and abstract screening, we selected studies that evaluate the validity of the new biomarkers on CKD diagnosis and prognosis in patients from different backgrounds. Additionally, we searched for additional publications in the references of the selected articles.

2. New Biomarkers for Chronic Kidney Disease Management

Renal disease is caused by an initial loss of nephrons; then, as a consequence of the kidney functional adaptations to the damage, disease progresses sequentially through different pathophysiological processes, leading to an irreversible state of fibrosis. Moreover, tubulointerstitial hypoxia, inflammation and oxidative stress are simultaneously a cause and effect of renal injury and form a vicious cycle in CKD progression.
The search for new biomarkers should focus on better indicators of renal dysfunction than GFR, and on markers of specific types of kidney injury, assessed in serum and/or urine. The study of specific biomarkers would allow the identification of kidney damage, and they should reflect the underlying pathophysiological processes of kidney damage [8], namely, changes in renal function, tubulointerstitial damage, endothelial dysfunction and inflammation, and/or cardiovascular risk (Figure 2).

2.1. Biomarkers of Renal Function

2.1.1. Beta Trace Protein (BTP) and β2-Microglobulin (B2M)

The assessment of renal function relies mainly on the estimation of GFR, using creatinine or creatinine and cystatin C-based equations. Because of the known limitations of these markers, several alternative markers have been studied, namely beta trace protein (BTP) and β2-microglobulin (B2M) (Table 1).
Beta trace protein and β2-microglobulin are low molecular weight proteins that are filtered by the glomeruli and almost completely reabsorbed by the proximal tubules. Since its urinary excretion is residual, the increase in these proteins has been proposed as potential serum markers of decreased GFR, and also as markers of tubular damage if its urinary excretion is elevated [9]. According to Inker et al. (2016) and Foster et al. (2017), BTP and B2M are not affected by ethnicity, and less influenced by age and gender than serum creatinine [10,11].
BTP, also known as prostaglandin D2 synthase, catalyzes the conversion of prostaglandin H2 to prostaglandin D2. It has been used as a marker of cerebrospinal fluid leakage since it is an important constituent of cerebral spinal fluid and is in much lower concentrations in blood [12]. Many studies have described and compared the diagnostic performance of BTP with the traditional markers of CKD [13,14,15], reporting that increased urinary and systemic BTP concentrations were highly correlated with creatinine and cystatin C concentrations [16,17]; moreover, the urinary concentration of BTP progressively increased, along with GFR reduction, and with a rise in its serum concentration [16]. A study conducted by Motawi et al. (2017) showed that serum BTP was higher in type 2 diabetes (T2D) CKD patients with microalbuminuria than in patients with normoalbuminuria, suggesting the potential of BTP in the early diagnosis of diabetic nephropathy [18]. These results are in accordance with previous findings from Dajak et al. (2011) showing high diagnostic accuracy for BTP to detect albuminuria (>30 mg/g) [19].
B2M is a component of the major histocompatibility class I molecule family that is expressed on the surface of most nucleated cells and is present in most biological fluids [20]. Serum and urinary concentrations of B2M increase with the progression of CKD and are particularly high in ESRD patients [20,21].
Several studies have also documented the association of both BTP and B2M with progression to ESRD, CVD development, and mortality [22,23,24]. In spite of the association of BTP and B2M with ESRD, only B2M levels were associated with mortality in a 14-year follow-up study in 250 T2D Pima Indians [22]. However, a larger study, comprising 3613 adults from the Chronic Renal Insufficiency Cohort study, showed that both BTP and B2M were independent predictors of ESRD and all-cause mortality. A cohort study carried out in 9703 participants from the Atherosclerosis Risk in Communities study confirmed the potential utility of measuring changes in B2M to predict worsening to ESRD. A 30% decline in kidney function, assessed using this novel filtration marker, was strongly associated with ESRD [24].
Some researchers used BTP and B2M to develop newer estimated GFR (eGFR) equations. However, in most studies, no advantages were found over the traditional equations used in traditional practice. Pottel et al. (2018) and White et al. (2019) described no additional benefits of adding BTP and B2M to creatinine and cystatin C equations [25,26]. However, a meta-analysis that included 23,318 individuals from six different studies compared the improvements in reclassification of eGFR, risk prediction of ESRD and mortality using BTP- and B2M-based eGFR equations. Compared to the traditional creatinine-based equations, eGFR BTP- and B2M-based equations improved the risk associations and fairly improved the prediction for ESRD and mortality (after adjustment for established risk factors). Moreover, the best performance was found using an eGFR equation that included a combination of both markers [27].

2.1.2. Klotho

Klotho is a transmembrane protein, mainly expressed in the proximal and distal tubular cells [28]. CKD patients present reduced levels of klotho. Klotho deficiency is positively correlated with kidney function decline, even in CKD patients at stages 1 and 2 [29,30]. Therefore, klotho was previously described as an extremely sensitive and early marker in CKD [29] since its levels reflect the degree of renal insufficiency. In accordance with such findings, Qian et al. (2018) reported that changes in soluble klotho could be used as indicators of CKD progression, since they correlated with changes in eGFR [31]. Likewise, a meta-analysis by Wang et al. (2018) reported a significant positive correlation between soluble klotho levels and eGFR in CKD patients [32].
In CKD patients, decreased klotho levels were also associated with increased albumin excretion [33], higher risk of CVD [34], mortality [35], and CKD related inflammation [36]. Moreover, klotho has a pathophysiological role in ion disorders, and might be used as a marker of abnormal phosphate and bone metabolism in these patients. Zheng et al. (2018) demonstrated that serum klotho levels were associated with the degree of mineral bone disorder in a group of 125 hemodialyzed patients. Patients with osteoporosis presented lower klotho levels than those with normal bone mass or with osteopenia [37]. In addition, a study conducted on 152 CKD patients showed that klotho levels were negatively correlated with serum phosphate levels, suggesting that decreased klotho aggravates the urinary phosphate excretion disorder [38].

2.2. Biomarkers of Tubular Lesions

Tubular function is impaired early in the disease course—sometimes, even before evident glomerular dysfunction. Several promising new biomarkers of tubular integrity have been studied (Table 2), namely neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), N-acetyl-β-D-glucosaminidase (NAG), liver-type fatty acid binding protein (L-FABP), and uromodulin (UMOD).

2.2.1. Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1) and N-acetyl-β-D-glucosaminidase (NAG)

The importance of neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1) and N-acetyl-β-D-glucosaminidase (NAG) as early indicators of tubular lesions has been documented, but some conflicting results were found. NGAL and KIM-1 are expressed in tubular epithelial cells in response to injury and have been proposed as early biomarkers of CKD [47,48]; their values are increase before the development of irreversible tubular atrophy and fibrosis.
NGAL is a ubiquitous lipocalin iron-carrying protein, mainly secreted by activated neutrophils in response to bacterial infection. It is also expressed in the renal tubular epithelial cells and released in case of cell damage [47]. Both systemic and urinary NGAL concentrations increase when tubular kidney damage occurs [49]. It is believed that NGAL has a protective role in case of renal damage, since it contributes to the recovery of the epithelium after injury [50]; it appears as a biomarker of tubular renal injury, and not of renal (dys)function. NGAL appears as a promising biomarker for early stages of CKD, since it has been associated with early decline in eGFR and albuminuria [49]. The findings of Abbasi et al. (2020) suggest that urinary NGAL levels increase before the onset of traditional markers (eGFR and albuminuria) in T2D patients [51], which indicates that urinary NGAL could be a complementary measurement in the early diagnosis of diabetic nephropathy. In line with this, a recent meta-analysis conducted by Kapoula et al. (2019) aimed to evaluate the diagnostic accuracy of NGAL for early predicting diabetic nephropathy. This analysis enrolled 22 studies, comprising a total of 683 healthy individuals and 3249 diabetic patients (488 with type 1 diabetes (T1D) and 2761 with T2D). The authors found that both serum and urinary NGAL showed an increasing trend alongside with albuminuria and eGFR aggravation. The highest concentrations of NGAL were found in patients with the highest disease severity. Moreover, NGAL showed a moderate to high capacity for early detection of diabetic nephropathy. Most previous published studies reported a similar tendency regarding NGAL for the diagnosis of diabetic nephropathy [52].
KIM-1 is a cellular receptor responsible for regulating immune cells activity in response to viral infections. It is not detectable in the normal kidney, but elevated levels were found in experimental and clinical kidney damage [48]. KIM-1 is a recognized biomarker for acute kidney injury (AKI), and it is also upregulated in CKD [53]. Zhang et al. (2018) reported that higher baseline concentrations of KIM-1 were associated with higher odds of incident CKD in a cohort of 324 adults with hypertension but without baseline kidney disease [54]. In patients with T2D and early stages of CKD (G1 and G2), serum and urinary NGAL, as well as urinary KIM-1, were increased in association with increased urine albumin-to-creatinine ratio, and appeared as significant predictors of albuminuria [55]. In a follow-up study of 527 adults with T1D, Bjornstad et al. (2018) reported that only NGAL (and not KIM-1) was associated with urine albumin-to-creatinine ratio and incident impaired GFR [56].
NAG is a glycosidase found mainly in the lysosomes of proximal tubular cells. Due to its molecular weight (130,000 Dalton), NAG cannot be filtered at the glomerulus; thus, increased urinary concentrations of NAG are signs of proximal tubular damage [57].
In order to predict progression of CKD in patients with chronic heart failure, Jungbauer et al. (2016) evaluated urinary NAG, NGAL and KIM-1 concentrations in 149 patients, who were followed for a period of 5 years. Strong associations of CKD progression with NAG and KIM-1, but not with NGAL, were found in these patients [58], suggesting their usefulness as cardiorenal markers. However, in a prospective cohort study comprising 250 patients at all CKD stages, NGAL was more strongly correlated with disease progression in more advanced CKD stages than KIM-1 and NAG. In addition, NGAL was the only predictor of ESRD and death [59].
The conflicting results may suggest that NGAL, KIM-1 and NAG have different behaviors depending on the CKD cause. Further studies should focus on the kinetics of NGAL, KIM-1 and NAG in CKD with different etiologies to identify their specific field as renal disease biomarkers.

2.2.2. Liver-Type Fatty Acid Binding Protein (L-FABP)

The liver-type fatty acid binding protein (L-FABP) is abundantly expressed in hepatocytes and in proximal renal tubular cells. Injury of the proximal tubular cells induces upregulation of the L-FABP gene, leading to increased L-FABP expression by these cells and, consequently, to an increase in the urinary L-FABP excretion [60]. The urinary levels of L-FABP have been correlated with the degree of tubulointerstitial damage in renal biopsies [61].
Urinary L-FABP seems to be useful in predicting AKI [62] and also AKI-to-CKD transition [63]. In T2D patients, L-FABP appears to be a more sensitive marker than proteinuria to predict CKD progression. Accordingly, Kathir et al. (2017) reported that urinary L-FABP was associated with a decline in GFR in CKD patients without albuminuria [64]. A prospective, observational, multicenter study, comprising 244 Japanese patients with CKD, correlated higher urinary L-FABP levels with the development of ESRD and CVD, irrespective of diabetes. Non-fatal or fatal CVD events and progression to ESRD were associated with higher L-FABP levels and low eGFR [65]. Similarly, Maeda et al. (2015) showed that L-FABP, as well as urinary albumin-to-creatinine ratio, could be useful in assessing cardiovascular damage in T2D patients at CKD stages 1 and 2, since they correlated with the elevation of cardiac markers and electrocardiogram abnormalities [66].

2.2.3. Uromodulin (UMOD)

Uromodulin (UMOD), also known as Tamm–Horsfall protein, is a kidney-specific protein, exclusively produced by the renal tubules, and it is involved in the control of water–electrolyte balance and in the defense against urinary tract bacterial infections [67]. Under normal conditions, UMOD is the most abundant protein in urine. In the case of CKD patients, with tubular atrophy and interstitial fibrosis, the urinary and serum UMOD concentrations are reduced. Rare mutations in the UMOD gene were associated with hereditary autosomal-dominant tubulointerstitial diseases [67].
An observational study that included 170 CKD patients at stages 1 to 5 pre-dialysis and 30 healthy individuals showed that serum UMOD levels were significantly lower in CKD patients, and correlated negatively with serum creatinine and cystatin C levels and positively with eGFR. Moreover, UMOD circulating levels were highly accurate in the assessment of CKD stages, showing a gradual decline with the progression of kidney disease [68]. Accordingly, Steubl et al. (2016) showed that plasma UMOD was capable of differentiating patients without CKD and with stage 1 CKD, contrarily to creatinine and cystatin C [69]. Furthermore, Scherberich et al. (2018) reported that declining serum UMOD concentrations are associated with loss of kidney function in patients with CKD at stages 1 to 5 and autoimmune kidney diseases, even in the absence of creatinine changes. Decreased levels of serum UMOD were further associated with the structural integrity of the renal parenchyma [70].

2.3. Biomarkers of Endothelial Dysfunction

Endothelial dysfunction begins in the early stages of CKD and progresses with renal disease severity [83,84,85,86], suggesting that it may be the key element linking CKD to the increased CV risk in these patients. The mechanisms underlying endothelial dysfunction in CKD include reduced nitric oxide (NO) production due to increased levels of endogenous NO synthase inhibitors, oxidative stress, inflammation, and vascular calcification [87,88]. Several endothelial dysfunction markers have been studied in the context of CKD. In this study, we focused on asymmetric dimethylarginine (ADMA) and fetuin-A, since these biomarkers reflect distinct pathophysiological alterations affecting endothelium integrity (Table 3).

2.3.1. Asymmetric Dimethylarginine (ADMA)

Asymmetric dimethylarginine (ADMA) is the most effective endogenous inhibitor of NO synthase, and its accumulation contributes to endothelial dysfunction and, therefore, to atherosclerotic changes [89]. In fact, ADMA is an independent risk marker for CVD development and for all-cause mortality [90].
In a recently published study, ADMA was positively associated with endothelial dysfunction and with CKD duration and severity in pre-dialysis patients [86]. Other studies found similar associations between ADMA levels and eGFR. A cross-sectional study conducted on 176 CKD patients showed a correlation between increasing plasma levels of ADMA and kidney function deterioration; moreover, stage 5 patients registered the highest elevation on ADMA plasma levels. The increase in ADMA was associated with by both eGFR < 60 mL/min/1.73 m2 and anemia, two risk factors for CVD [84]. Inverse associations between eGFR and ADMA concentrations were also found in an elderly Korean cohort; in this study, the mean ADMA levels were significantly higher in subjects with eGFR < 60 mL/min/1.73 m2 than in those with a higher eGFR [91]. A systematic review and meta-analysis conducted by Wang et al. (2018) that analyzed six prospective and cross-sectional studies correlated circulating ADMA concentrations with carotid intima-media thickness in CKD patients. Since carotid intima-media thickness is an important predictor of atherosclerosis, the researchers proposed that elevated circulating ADMA levels are predictors of atherosclerotic disease development in these patients, and not only a marker of subclinical atherosclerosis [92]. Furthermore, Bartnicki et al. (2016) found that left ventricular structural and functional pathological changes occur in parallel with elevated serum ADMA concentrations [93]. Triches et al. (2018) showed that higher circulating ADMA levels were associated with new-onset microalbuminuria and/or with a progression in initial albuminuria in at least 30% in a follow-up study of hypertensive and both hypertensive and diabetic patients [85]. An increase in ADMA may precede albuminuria development, suggesting that ADMA levels are an earlier biomarker of CKD in this population. Subjects who presented increased ADMA values during the follow-up period progressed to the later stages of CKD [85]. Moreover, the magnitude of the ADMA increase might be a marker of the rate of kidney disease progression. Additionally, Seliger et al. (2016) demonstrated in a group of older hypertensive patients with and without CKD, that laser Doppler flowmetry-based measures of endothelial dysfunction and microvascular reactivity are the strongest determinants of albuminuria, irrespective of diabetes status [94]. This study provides further evidence that endothelial function is correlated with albuminuria and that albuminuria may reflect glomerular microvascular dysfunction.

2.3.2. Fetuin-A

Fetuin-A, a vascular calcification inhibitor, is also a risk factor for the development of endothelial dysfunction in CKD patients [95]. Reduced serum levels of fetuin-A have been associated with increased CV mortality in maintenance hemodialysis patients [96]. However, the relationship between vascular calcification and endothelial dysfunction is not so clear in patients with early CKD.
Mutluay et al. (2019) conducted a study on 238 CKD patients at stages 3 and 4 and with ESRD in order to compare fetuin-A levels between them. Fetuin-A levels were significantly lower in ESRD patients than in patients with stages 3 or 4 of CKD. Moreover, in ESRD patients, the lower levels of fetuin-A were associated with higher vascular calcification scores and carotid intima-media thickness [97]. A meta-analysis of 13 studies comprising 5169 patients at all stages of CKD aimed to determine the relationship between circulating fetuin-A levels and the risk for all-cause mortality. Data collected for this meta-analysis by Zhou et al. (2019) suggest that there is a significant association between low fetuin-A levels and higher risk of mortality, independent of diabetes and inflammation, in dialysis patients, but not in non-dialysis patients. In dialyzed patients, a 0.1 g/L increase in fetuin-A levels lowers the risk for all-cause mortality in 8% [98].
In addition to its role in endothelial dysfunction, fetuin-A has also been associated with inflammation [96,99] and nutritional status [100,101], which is a common complication associated with increased mortality in CKD patients [102]. Dialyzed patients have poorer nutritional status than non-dialyzed patients [103], which might explain the differences in fetuin-A levels found between these populations.

2.4. Biomarkers of Inflammation

Several studies in the literature suggest that activation of the inflammatory processes in the early stages of CKD drives kidney function impairment and propose that the assessment of inflammatory markers might help in earlier CKD diagnosis. Increased inflammatory markers and changes in GFR have been widely reported [108,109,110]. Moreover, inflammation is a risk factor for CKD-associated morbidity and may contribute to cardiovascular mortality in CKD patients [111] (Table 4).
Increased levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) involved in the inflammatory response predict poor outcome in patients with renal disease [112]. A proteomic approach identified an increased expression of serum IL-6 and TNF-α in the early stages of CKD, which highlights the importance of these inflammatory biomarkers for CKD patients’ diagnoses and management [113]. An observational study conducted by Kamińska et al. (2019), associated IL-6, but not TNF-α, to coronary artery calcification, a risk factor for cardiovascular mortality, in CKD and ESRD patients [114].
The overexpression of other pro-inflammatory cytokines, such as interleukin-8 (IL-8) and interleukin-18 (IL-18), has also been linked to renal function decline [113,115,116]. Likewise, soluble TNF receptors 1 and 2 (sTNFR1 and sTNFR2) showed an important role in the progression of atherosclerosis and kidney diseases [117,118].
Pentraxin 3 (PTX3) is produced by resident and innate immunity cells in peripheral tissues and increases rapidly in response to primary local activation of inflammation [119,120]. A cross-sectional study comprising two community-based cohorts of elderly subjects without CKD found that increased levels of PTX3 were associated with decreased eGFR and could independently predict incident CKD [121]. In ESRD patients undergoing dialysis, plasma PTX3 levels were shown to be more accurate than C-reactive protein (CRP), a traditional inflammatory marker, in predicting all-cause mortality. Moreover, plasma PTX3 levels were associated with other inflammatory markers (IL-6 and TNF-α), with adipokines disturbances and with the worst lipid risk profile [122]. This recent study highlights the association of PTX3 with multiple risk factors, such as inflammation and malnutrition. Furthermore, PTX3 was postulated to be a predictive marker of mortality in patients with advanced CKD [122,123].
Growth differentiation factor-15 (GDF-15) is a member of the transforming growth factor beta cytokine superfamily, and its expression may be induced in response to ischemia. GDF-15 was significantly associated with increased risk of CKD progression in several studies [124,125,126,127]. Nair et al. (2017) showed that circulating GDF-15 levels were strongly correlated with intrarenal expression of GDF-15, stating that GDF-15 may be a marker for intrarenal signaling pathways associated with CKD development and progression [124]. The Framingham study found associations between increased GDF-15 levels and the development of incident CKD with rapid decline of kidney function [128]. This study was limited to participants without CKD and suggests that increases in GDF-15 may help to identify higher risk for CKD development. Tuegel et al. (2018) found that elevated serum levels of GFD-15 were associated with an increased rate of heart failure in adults with CKD, but had no associations with atherosclerotic CVD events [126].
Inflammation and oxidative stress may contribute to DNA damage. In fact, DNA damage has been correlated with enhanced inflammatory states in different conditions, including CKD [129]. The quantification of circulating cell-free DNA (cfDNA), a measure of DNA damage, was proven to be helpful in detecting tumors in patients with renal cell carcinoma [130], and in predicting AKI after cardiac surgery [131].
Patients with CKD present different types of DNA damage and increased circulating levels of cfDNA [129]. Coimbra et al. (2017) analyzed the degree of genomic damage in ESRD patients undergoing hemodialysis (HD), and found that patients presented higher levels of CRP and cfDNA, correlating the persistent inflammatory state of those patients with the degree of DNA injury [132]. Furthermore, in non-dialyzed patients, urinary levels of cfDNA were predictors of unfavorable renal outcomes [133]. These findings were consistent with the results of Li et al. (2020), which demonstrated that increased serum cfDNA levels were associated with an increased risk of diabetic nephropathy in a cohort of diabetic patients [134], suggesting the potential of cfDNA as a biomarker of disease progression.
Watson et al. (2019) developed a Kidney Injury Test (KIT) based on the composite measurement and validation of six biomarkers across a set of 397 urine samples from patients with CKD, or with an increased risk for CKD (diabetic or hypertensive patients). The KIT analyzed DNA, protein, and metabolite markers, including cfDNA. In patients with normal renal function (eGFR) ≥ 90 mL/min/1.73 m2), the KIT score clearly identified those with predisposing risk factors for CKD, which could not be detected by eGFR or proteinuria [135].

2.5. Metabolomic Studies on CKD Biomarkers

In patients with CKD, metabolomic profiling identified several metabolites associated with alterations in carbohydrates, amino acids, nucleotides, and lipids metabolism. Since the progression of CKD is concomitant with metabolism alterations, these metabolites are being studied as potential biomarkers (Table 5).
The identification of these small molecules could help in assessing the multiple pathophysiological changes in CKD, since they might reflect early impairments in specific pathways. Lee et al. (2016) demonstrated that the presence of diabetes in CKD patients induces metabolic changes that are reflected in the levels of serum metabolites, such as arginine, N-acetyl-glycoprotein, glutamine, alanine and leucine [139]. CKD patients with diabetes present more severe metabolic changes than those without diabetes. However, these effects are particularly enhanced in the early stages rather than in advanced CKD [139]. A prospective study that enrolled 193 patients who developed CKD during the follow-up period and 193 matched controls found that decreased urinary levels of glycine and histidine were associated with incident CKD [140]. Additionally, Guo et al. (2019) identified 5-methoxytryptophan, canavaninosuccinate, acetylcarnitine, tiglylcarnitine and taurine as potential predictors of early CKD in a study population of 587 adults at all stages of CKD and of 116 healthy controls [141].
Metabolomic approaches identified that kynurenine, a metabolite of the amino acid L-tryptophan and an intermediate in the formation of NAD+, was associated with decreased eGFR and that alterations in the kynurenine/tryptophan ratio were associated with the presence of renal disease [142]. Additionally, kynurenine increases along with CKD progression, since patients with higher CKD stages exhibit higher kynurenine levels [143]. Debnath et al. (2017) showed that kynurenine was positively associated with TNF-α, suggesting that increased kynurenine might result from the ongoing inflammatory process [144].
Moreover, Ma et al. (2019) demonstrated that abnormalities in triacylglycerols and cardiolipins–phosphatidylethanolamines could discriminate CKD progression, preceding ESRD by several years [145]. Furthermore, Hu et al. (2018) identified three serum metabolites (fumarate, allantoin, and ribonate) associated with all-cause mortality from 299 CKD patients from the Modification of Diet in Renal Disease study, and 963 patients with CKD from the African American Study of Kidney Disease and Hypertension cohort [146].
Other potential metabolites related to kidney damage and/or GFR decline include citrulline [142,147], 1,5-anhydroglucitol [148,149], metabolites of the citric oxide pathway [150], and several others reviewed by Hocher and Adamski (2017) [151] and Cañadas-Garr et al. (2019) [152].
Besides metabolomic studies, there are other omic studies, namely proteomics, that are useful for the study of CKD. A comparison of CKD patients’ proteomic urinary profiles against those of healthy controls demonstrated that using a panel of 273 CKD-specific peptides could discriminate between the two groups [153]. The urinary peptide-based classifier CKD273 has been validated in different longitudinal and cross-sectional studies [154] and has sufficient sensitivity and specificity to allow differential diagnosis of CKD different etiologies [153]. The CKD273 represents one of most notable advances from proteomic studies of CKD biomarkers. The CKD273 is now commercially available as a non-invasive diagnostic test, allowing not only an earlier detection of CKD, but also patient stratification. Accordingly, in a cohort of patients with T2D and normoalbuminuria, the CKD273 proteomic biomarker panel was able to predict early diabetic nephropathy [155].

3. Future Perspectives and Conclusions

There is an emerging need for the identification of reliable early biomarkers of kidney injury, of progression of the disease and of morbidity and mortality risk. The reliance on only traditional biomarkers may result in a long time lapse, along which successful interventions could be applied. Most of these potentially new biomarkers identified from experimental studies may detect renal injury earlier than traditional biomarkers. Moreover, newer biomarkers can provide information about the pathophysiological mechanism (s) underlying renal disease, predict disease progression, severity and associated cardiovascular and/or all-cause mortality.
Creatinine limitations have been well known for more than thirty years [168]. However, creatinine is still the standard biomarker used for CKD evaluation in clinical practice. Newer glomerular filtration markers, such as BTP and B2M, have proven their potential to improve the accuracy and the predictive value of GFR estimation. With the increased use of cystatin C, BTP and B2M, GFR estimation is likely to undergo further improvements [18,26]. Other markers, such as NGAL, KIM-1 and L-FABP might be helpful in identifying early tubular damage, especially in the creatinine-blind range, and before pathological and irreversible changes occur. Moreover, their specificity allows the recognition of kidney damage separately from changes in kidney function. The initiation and the progression of endothelial dysfunction, closely related to the inflammatory response, is simultaneously a cause and a consequence of both CKD and CVD [110], which highlights the importance of early detection of such pathological pathways through early endothelial dysfunction and/or inflammatory markers assessment.
Advancing laboratory techniques that allow the concomitant analysis of multiple biomarkers are currently being used and have largely impacted the discovery of new biomarkers. Dozens of dysregulated peptides and metabolites were identified by proteomic and metabolomic studies. Furthermore, microRNA analysis studies have highlighted its implication in the pathogenesis of CKD [169,170,171], particularly in kidney fibrotic transformation [172]. Different microRNA expression profiles were identified under different renal disease conditions [173]. Due to microRNAs functional promiscuity, since they usually target proteins from various pathways, confirmation studies are still required to clarify its role in the clinical diagnostic setting. Despite their promising potential, metabolite profiling technologies and microRNA analysis are still expensive and time consuming, explaining why their application is not widely available.
It is unlikely that a single biomarker can predict CKD progression and identify the multiple pathophysiological processes involved in CKD progression or the underlying primary renal disease. Instead, a panel measuring multiple biomarkers seems to be a more reasonable approach to better predict CKD development and to access the outcomes of the disease, since there are several different mechanisms by which CKD can result. Additionally, the incorporation of multiple serum and/or urinary biomarkers is likely to be synergetic in predicting renal failure while decreasing the impact of non-renal determinants for each biomarker alone [174]. Panels of biomarkers for earlier detection of CKD are expected to include biomarkers related to the primary disease cause, while biomarkers for predicting disease progression are more likely to be related to the sequentially reduced renal function. Although it seems reasonable, the availability of such tools depends on the characterization of patients’ profiles against healthy controls and the validation of methods for analytical procedures.
CKD burden is not limited to the disease itself, extending to ESRD- and CKD-related CVD and other complications. Identification of CKD at early stages allows more rapid interventions in order to control disease progression and management of risk factors. This will translate in better patients’ prognoses and economic benefits related to decreased healthcare expenses.
In summary, further validation for most of these new potential biomarkers requires larger studies with standardized methodologies in order to be implemented in routine CKD management, either for an early diagnosis or for the detection of disease worsening. Moreover, the search for panel (s) of biomarkers that can synergistically detect renal disease or a poor outcome for renal patients is important.

Author Contributions

Conceptualization, I.L., A.S.-S., L.B., F.R.; writing—original draft preparation, I.L.; writing—review and ed iting, I.L., A.S.-S., L.B., F.R., I.B., R.A.; supervision, A.S.-S., L.B., F.R. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by Applied Molecular Biosciences Unit (UCIBIO) and financed by FEDER COMPETE2020 funds (UIDB/04378/2020).

Acknowledgments

This work was supported by national funds from Fundação para a Ciência e Tecnologia (FCT) & Ministério da Ciência, Tecnologia e Ensino Superior (MCTES); by FEDER COMPETE2020 (UIDP/04539/2020); by PTDC/SAU-NUT/31712/2017, POCI-01-0145-FEDER-007440 and POCI-01-0145-FEDER-031712, and by FCT doctoral grant SFRH/BD/145939/2019; by funds from Portugal Regional Coordination and Development Commissions (Norte-01-0145-FEDER-000024; Centro-01-0145-FEDER-000012). Figure 2 was created with biorender.com.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

CKDChronic kidney disease
ESRDEnd-stage renal disease
CVDCardiovascular disease
GFRGlomerular filtration rate
BTPBeta trace protein
B2Mβ2-microglobulin
T2DType 2 diabetes
eGFREstimated glomerular filtration rate
NGALNeutrophil gelatinase-associated lipocalin
KIM-1Kidney injury molecule-1
NAGN-acetyl-β-D-glucosaminidase
L-FABPLiver-type fatty acid binding protein
UMODUromodulin
T1DType 1 diabetes
AKIAcute kidney injury
NONitric oxide
ADMAAsymmetric dimethylarginine
IL-6Interleukin-6
TNF-αTumor necrosis factor-α
PTX3Pentraxin 3
CRPC-reactive protein
GDF-15Growth differentiation factor-15
cf-DNACell-free DNA

References

  1. Foundation, N.K. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am. J. Kidney Dis. 2002, 39, S1–S266. [Google Scholar]
  2. Eckardt, K.U.; Coresh, J.; Devuyst, O.; Johnson, R.J.; Kottgen, A.; Levey, A.S.; Levin, A. Evolving importance of kidney disease: From subspecialty to global health burden. Lancet 2013, 382, 158–169. [Google Scholar] [CrossRef] [Green Version]
  3. Schlondorff, D.O. Overview of factors contributing to the pathophysiology of progressive renal disease. Kidney Int. 2008, 74, 860–866. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Yamaguchi, J.; Tanaka, T.; Nangaku, M. Recent advances in understanding of chronic kidney disease. F1000Res 2015, 4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Zhang, W.R.; Parikh, C.R. Biomarkers of Acute and Chronic Kidney Disease. Annu. Rev. Physiol. 2019, 81, 309–333. [Google Scholar] [CrossRef] [PubMed]
  6. Levin, A.; Stevens, P.E.; Bilous, R.W.; Coresh, J.; De Francisco, A.L.M.; De Jong, P.E.; Griffith, K.E.; Hemmelgarn, B.R.; Iseki, K.; Lamb, E.J.; et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2012, 3, 1–150. [Google Scholar] [CrossRef]
  7. Levey, A.S.; Coresh, J. Chronic kidney disease. Lancet 2012, 379, 165–180. [Google Scholar] [CrossRef]
  8. Santos-Silva, A.; Costa, E.; Alves, R. Chronic Kidney Disease. In Biomarkers of Cardiometabolic Risk, Inflammation and Disease; Palavra, F., Reis, F., Marado, D., Sena, A., Eds.; Springer International Publishing: Cham, Switzerland, 2015; pp. 95–111. [Google Scholar]
  9. George, J.A.; Gounden, V. Novel glomerular filtration markers. Adv. Clin. Chem. 2019, 88, 91–119. [Google Scholar] [CrossRef] [PubMed]
  10. Inker, L.A.; Tighiouart, H.; Coresh, J.; Foster, M.C.; Anderson, A.H.; Beck, G.J.; Contreras, G.; Greene, T.; Karger, A.B.; Kusek, J.W.; et al. GFR Estimation Using beta-Trace Protein and beta2-Microglobulin in CKD. Am. J. Kidney Dis. 2016, 67, 40–48. [Google Scholar] [CrossRef] [Green Version]
  11. Foster, M.C.; Levey, A.S.; Inker, L.A.; Shafi, T.; Fan, L.; Gudnason, V.; Katz, R.; Mitchell, G.F.; Okparavero, A.; Palsson, R.; et al. Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in the Elderly: AGES-Kidney and MESA-Kidney. Am. J. Kidney Dis. 2017, 70, 406–414. [Google Scholar] [CrossRef]
  12. Filler, G.; Kusserow, C.; Lopes, L.; Kobrzyński, M. Beta-trace protein as a marker of GFR--history, indications, and future research. Clin. Biochem. 2014, 47, 1188–1194. [Google Scholar] [CrossRef] [PubMed]
  13. Spanaus, K.S.; Kollerits, B.; Ritz, E.; Hersberger, M.; Kronenberg, F.; von Eckardstein, A. Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin. Chem. 2010, 56, 740–749. [Google Scholar] [CrossRef] [PubMed]
  14. Donadio, C. Serum and urinary markers of early impairment of gfr in chronic kidney disease patients: Diagnostic accuracy of urinary β-trace protein. Am. J. Physiol. Renal. Physiol. 2010, 299, f1407–f1423. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Chen, n.; Shi, h.; Zhang, L.; Zuo, L.; Xie, J.; Xie, D.; Karger, A.B.; Miao, S.; Ren, H.; Zhang, W.; et al. GFR Estimation Using a Panel of Filtration Markers in Shanghai and Beijing. Kidney Med. 2020, 2, 172–180. [Google Scholar] [CrossRef] [PubMed]
  16. Donadio, C.; Bozzoli, L. Urinary beta-trace protein: A unique biomarker to screen early glomerular filtration rate impairment. Medicine 2016, 95, e5553. [Google Scholar] [CrossRef] [PubMed]
  17. Ewadh, M. Beta trace protein level as a better diagnostic marker of renal impairment in patients with chronic kidney disease, diabetes mellitus, and renal transplants. J. Pharm. Sci. Res. 2018, 10, 1615–1618. [Google Scholar]
  18. Motawi, T.K.; Shehata, N.I.; ElNokeety, M.M.; El-Emady, Y.F. Potential serum biomarkers for early detection of diabetic nephropathy. Diabetes Res. Clin. Pract. 2018, 136, 150–158. [Google Scholar] [CrossRef]
  19. Dajak, M.; Ignjatovic, S.; Stojimirovic, B.; Gajic, S.; Majkic-Singh, N. Evaluation of renal damage by urinary beta-trace protein in patients with chronic kidney disease. Clin. Lab. 2011, 57, 29–36. [Google Scholar]
  20. Drüeke, T.B.; Massy, Z.A. Beta2-microglobulin. Semin. Dial. 2009, 22, 378–380. [Google Scholar] [CrossRef]
  21. Stefanović, V.; Djukanović, L.; Cukuranović, R.; Bukvić, D.; Ležaić, V.; Marić, I.; Ogrizovic, S.S.; Jovanović, I.; Vlahovic, P.; Pešić, I.; et al. Beta2-microglobulin and alpha1-microglobulin as markers of Balkan endemic nephropathy, a worldwide disease. Ren. Fail. 2011, 33, 176–183. [Google Scholar] [CrossRef]
  22. Foster, M.C.; Inker, L.A.; Hsu, C.Y.; Eckfeldt, J.H.; Levey, A.S.; Pavkov, M.E.; Myers, B.D.; Bennett, P.H.; Kimmel, P.L.; Vasan, R.S.; et al. Filtration markers as predictors of ESRD and mortality in Southwestern American Indians with type 2 diabetes. Am. J. Kidney Dis. 2015, 66, 75–83. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Rebholz, C.M.; Inker, L.A.; Chen, Y.; Liang, M.; Foster, M.C.; Eckfeldt, J.H.; Kimmel, P.L.; Vasan, R.S.; Feldman, H.I.; Sarnak, M.J.; et al. Risk of ESRD and Mortality Associated with Change in Filtration Markers. Am. J. Kidney Dis. 2017, 70, 551–560. [Google Scholar] [CrossRef] [PubMed]
  24. Rebholz, C.M.; Grams, M.E.; Matsushita, K.; Selvin, E.; Coresh, J. Change in novel filtration markers and risk of ESRD. Am. J. Kidney Dis. 2015, 66, 47–54. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Pottel, H.; Schaeffner, E.; Ebert, N. Evaluating the diagnostic value of rescaled beta-trace protein in combination with serum creatinine and serum cystatin C in older adults. Clin. Chim. Acta 2018, 480, 206–213. [Google Scholar] [CrossRef] [PubMed]
  26. White, C.A.; Allen, C.M.; Akbari, A.; Collier, C.P.; Holland, D.C.; Day, A.G.; Knoll, G.A. Comparison of the new and traditional CKD-EPI GFR estimation equations with urinary inulin clearance: A study of equation performance. Clin. Chim. Acta 2019, 488, 189–195. [Google Scholar] [CrossRef]
  27. Inker, L.A.; Coresh, J.; Sang, Y.; Hsu, C.Y.; Foster, M.C.; Eckfeldt, J.H.; Karger, A.B.; Nelson, R.G.; Liu, X.; Sarnak, M.; et al. Filtration Markers as Predictors of ESRD and Mortality: Individual Participant Data Meta-Analysis. Clin. J. Am. Soc. Nephrol. 2017, 12, 69–78. [Google Scholar] [CrossRef] [Green Version]
  28. Buchanan, S.; Combet, E.; Stenvinkel, P.; Shiels, P.G. Klotho, Aging, and the Failing Kidney. Front. Endocrinol. 2020, 11, 560. [Google Scholar] [CrossRef]
  29. Hu, M.-C.; Kuro-o, M.; Moe, O.W. Klotho and kidney disease. J. Nephrol. 2010, 23 (Suppl. 16), S136–S144. [Google Scholar]
  30. Zou, D.; Wu, W.; He, Y.; Ma, S.; Gao, J. The role of klotho in chronic kidney disease. BMC Nephrol. 2018, 19, 285. [Google Scholar] [CrossRef] [Green Version]
  31. Qian, J.; Zhong, J.; Yan, M.; Cheng, P.; Shi, H.; Hao, C.; Gu, Y.; Lai, L. Circulating α-Klotho is Related to Plasma Aldosterone and Its Follow-Up Change Predicts CKD Progression. Kidney Blood Press. Res. 2018, 43, 836–846. [Google Scholar] [CrossRef]
  32. Wang, Q.; Su, W.; Shen, Z.; Wang, R. Correlation between Soluble α-Klotho and Renal Function in Patients with Chronic Kidney Disease: A Review and Meta-Analysis. Biomed. Res. Int. 2018, 2018, 9481475. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Inci, A.; Sari, F.; Coban, M.; Olmaz, R.; Dolu, S.; Sarıkaya, M.; Yılmaz, N. Soluble Klotho and fibroblast growth factor 23 levels in diabetic nephropathy with different stages of albuminuria. J. Investig. Med. 2016, 64, 1128–1133. [Google Scholar] [CrossRef] [PubMed]
  34. Silva, A.P.; Mendes, F.; Carias, E.; Gonçalves, R.B.; Fragoso, A.; Dias, C.; Tavares, N.; Café, H.M.; Santos, N.; Rato, F.; et al. Plasmatic Klotho and FGF23 Levels as Biomarkers of CKD-Associated Cardiac Disease in Type 2 Diabetic Patients. Int. J. Mol. Sci. 2019, 20, 1536. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Memmos, E.; Sarafidis, P.; Pateinakis, P.; Tsiantoulas, A.; Faitatzidou, D.; Giamalis, P.; Vasilikos, V.; Papagianni, A. Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis. BMC Nephrol. 2019, 20, 217. [Google Scholar] [CrossRef] [Green Version]
  36. He, T.; Xiong, J.; Huang, Y.; Zheng, C.; Liu, Y.; Bi, X.; Liu, C.; Han, W.; Yang, K.; Xiao, T.; et al. Klotho restrain RIG-1/NF-κB signaling activation and monocyte inflammatory factor release under uremic condition. Life Sci. 2019, 231, 116570. [Google Scholar] [CrossRef]
  37. Zheng, S.; Chen, Y.; Zheng, Y.; Zhou, Z.; Li, Z. Correlation of serum levels of fibroblast growth factor 23 and Klotho protein levels with bone mineral density in maintenance hemodialysis patients. Eur. J. Med. Res. 2018, 23, 18. [Google Scholar] [CrossRef] [Green Version]
  38. Liu, Z.; Zhou, H.; Chen, X.; Chen, H.; Wang, Y.; Wang, T.; Cai, L.; Hong, Y.; Ke, H.; Zheng, J. Relationship between cFGF23/Klotho ratio and phosphate levels in patients with chronic kidney disease. Int. Urol. Nephrol. 2019, 51, 503–507. [Google Scholar] [CrossRef]
  39. Hong, Y.A.; Lim, J.H.; Kim, M.Y.; Kim, Y.; Yang, K.S.; Chung, B.H.; Chung, S.; Choi, B.S.; Yang, C.W.; Kim, Y.S.; et al. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease. Clin. Exp. Nephrol. 2015, 19, 208–215. [Google Scholar] [CrossRef]
  40. Foster, M.C.; Coresh, J.; Hsu, C.Y.; Xie, D.; Levey, A.S.; Nelson, R.G.; Eckfeldt, J.H.; Vasan, R.S.; Kimmel, P.L.; Schelling, J.; et al. Serum beta-Trace Protein and beta2-Microglobulin as Predictors of ESRD, Mortality, and Cardiovascular Disease in Adults With CKD in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am. J. Kidney Dis. 2016, 68, 68–76. [Google Scholar] [CrossRef] [Green Version]
  41. Drew, D.A.; Katz, R.; Kritchevsky, S.; Ix, J.; Shlipak, M.; Gutiérrez, O.M.; Newman, A.; Hoofnagle, A.; Fried, L.; Semba, R.D.; et al. Association between Soluble Klotho and Change in Kidney Function: The Health Aging and Body Composition Study. J. Am. Soc. Nephrol. 2017, 28, 1859–1866. [Google Scholar] [CrossRef] [Green Version]
  42. Ebert, N.; Koep, C.; Schwarz, K.; Martus, P.; Mielke, N.; Bartel, J.; Kuhlmann, M.; Gaedeke, J.; Toelle, M.; van der Giet, M.; et al. Beta Trace Protein does not outperform Creatinine and Cystatin C in estimating Glomerular Filtration Rate in Older Adults. Sci. Rep. 2017, 7, 12656. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Khosravi, N.; Asgari, M.; Khalessi, N.; Hoseini, R.; Khosravi, N. Serum Beta-Trace Protein for Assessment of Kidney Function in Neonates. Iran. J. Kidney Dis. 2018, 12, 11–13. [Google Scholar] [PubMed]
  44. Liu, Q.F.; Yu, L.X.; Feng, J.H.; Sun, Q.; Li, S.S.; Ye, J.M. The Prognostic Role of Klotho in Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis. Dis. Markers 2019, 2019, 6468729. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Yue, L.; Pan, B.; Shi, X.; Du, X. Comparison between the Beta-2 Microglobulin-Based Equation and the CKD-EPI Equation for Estimating GFR in CKD Patients in China: ES-CKD Study. Kidney Dis. 2020, 6, 204–214. [Google Scholar] [CrossRef] [PubMed]
  46. Jung, J.Y.; Ro, H.; Chang, J.H.; Kim, A.J.; Lee, H.H.; Han, S.H.; Yoo, T.H.; Lee, K.B.; Kim, Y.H.; Kim, S.W.; et al. Mediation of the relationship between proteinuria and serum phosphate: Insight from the KNOW-CKD study. PLoS ONE 2020, 15, e0235077. [Google Scholar] [CrossRef]
  47. Devarajan, P. Neutrophil gelatinase-associated lipocalin (NGAL): A new marker of kidney disease. Scand J. Clin. Lab. Invest. Suppl. 2008, 241, 89–94. [Google Scholar] [CrossRef] [Green Version]
  48. Huo, W.; Zhang, K.; Nie, Z.; Li, Q.; Jin, F. Kidney injury molecule-1 (KIM-1): A novel kidney-specific injury molecule playing potential double-edged functions in kidney injury. Transplant. Rev. 2010, 24, 143–146. [Google Scholar] [CrossRef]
  49. Ning, M.; Mao, X.; Niu, Y.; Tang, B.; Shen, H. Usefulness and limitations of neutrophil gelatinase-associated lipocalin in the assessment of kidney diseases. J. Lab. Precis. Med. 2018, 3, 1. [Google Scholar] [CrossRef]
  50. Bolignano, D.; Donato, V.; Coppolino, G.; Campo, S.; Buemi, A.; Lacquaniti, A.; Buemi, M. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am. J. Kidney Dis. 2008, 52, 595–605. [Google Scholar] [CrossRef]
  51. Abbasi, F.; Moosaie, F.; Khaloo, P.; Dehghani Firouzabadi, F.; Fatemi Abhari, S.M.; Atainia, B.; Ardeshir, M.; Nakhjavani, M.; Esteghamati, A. Neutrophil Gelatinase-Associated Lipocalin and Retinol-Binding Protein-4 as Biomarkers for Diabetic Kidney Disease. Kidney Blood Press. Res. 2020, 45, 222–232. [Google Scholar] [CrossRef]
  52. Kapoula, G.V.; Kontou, P.I.; Bagos, P.G. Diagnostic Accuracy of Neutrophil Gelatinase-Associated Lipocalin for Predicting Early Diabetic Nephropathy in Patients with Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. J. Appl. Lab. Med. 2019, 4, 78–94. [Google Scholar] [CrossRef] [PubMed]
  53. Sabbisetti, V.S.; Waikar, S.S.; Antoine, D.J.; Smiles, A.; Wang, C.; Ravisankar, A.; Ito, K.; Sharma, S.; Ramadesikan, S.; Lee, M.; et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J. Am. Soc. Nephrol. 2014, 25, 2177–2186. [Google Scholar] [CrossRef] [PubMed]
  54. Zhang, W.R.; Craven, T.E.; Malhotra, R.; Cheung, A.K.; Chonchol, M.; Drawz, P.; Sarnak, M.J.; Parikh, C.R.; Shlipak, M.G.; Ix, J.H. Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure Reduction: A Case-Control Study. Ann. Intern. Med. 2018, 169, 610–618. [Google Scholar] [CrossRef] [PubMed]
  55. Żyłka, A.; Dumnicka, P.; Kuśnierz-Cabala, B.; Gala-Błądzińska, A.; Ceranowicz, P.; Kucharz, J.; Ząbek-Adamska, A.; Maziarz, B.; Drożdż, R.; Kuźniewski, M. Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients. Mediat. Inflamm. 2018, 2018, 7659243. [Google Scholar] [CrossRef] [Green Version]
  56. Bjornstad, P.; Pyle, L.; Cherney, D.Z.I.; Johnson, R.J.; Sippl, R.; Wong, R.; Rewers, M.; Snell-Bergeon, J.K. Plasma biomarkers improve prediction of diabetic kidney disease in adults with type 1 diabetes over a 12-year follow-up: CACTI study. Nephrol. Dial. Transplant. 2018, 33, 1189–1196. [Google Scholar] [CrossRef]
  57. Skálová, S. The diagnostic role of urinary N-acetyl-beta-D-glucosaminidase (NAG) activity in the detection of renal tubular impairment. Acta Med. 2005, 48, 75–80. [Google Scholar]
  58. Jungbauer, C.G.; Uecer, E.; Stadler, S.; Birner, C.; Buchner, S.; Maier, L.S.; Luchner, A. N-acteyl-ss-D-glucosaminidase and kidney injury molecule-1: New predictors for long-term progression of chronic kidney disease in patients with heart failure. Nephrology 2016, 21, 490–498. [Google Scholar] [CrossRef]
  59. Lobato, G.R.; Lobato, M.R.; Thome, F.S.; Veronese, F.V. Performance of urinary kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and N-acetyl-beta-D-glucosaminidase to predict chronic kidney disease progression and adverse outcomes. Braz. J. Med. Biol. Res. 2017, 50, e6106. [Google Scholar] [CrossRef] [Green Version]
  60. Xu, Y.; Xie, Y.; Shao, X.; Ni, Z.; Mou, S. L-FABP: A novel biomarker of kidney disease. Clin. Chim. Acta 2015, 445, 85–90. [Google Scholar] [CrossRef]
  61. Negishi, K.; Noiri, E.; Doi, K.; Maeda-Mamiya, R.; Sugaya, T.; Portilla, D.; Fujita, T. Monitoring of Urinary L-Type Fatty Acid-Binding Protein Predicts Histological Severity of Acute Kidney Injury. Am. J. Pathol. 2009, 174, 1154–1159. [Google Scholar] [CrossRef] [Green Version]
  62. Suzuki, G.; Ichibayashi, R.; Yamamoto, S.; Nakamichi, Y.; Watanabe, M.; Honda, M. Clinical significance of urinary L-FABP in the emergency department. Int. J. Emerg. Med. 2019, 12, 24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Ichikawa, D.; Kamijo-Ikemori, A.; Sugaya, T.; Ohata, K.; Hisamichi, M.; Hoshino, S.; Kimura, K.; Shibagaki, Y. Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia-reperfusion. Nephrology 2018, 23, 308–316. [Google Scholar] [CrossRef] [PubMed]
  64. Khatir, D.S.; Bendtsen, M.D.; Birn, H.; Norregaard, R.; Ivarsen, P.; Jespersen, B.; Buus, N.H. Urine liver fatty acid binding protein and chronic kidney disease progression. Scand. J. Clin. Lab. Invest. 2017, 77, 549–554. [Google Scholar] [CrossRef] [PubMed]
  65. Matsui, K.; Kamijo-Ikemori, A.; Imai, N.; Sugaya, T.; Yasuda, T.; Tatsunami, S.; Toyama, T.; Shimizu, M.; Furuichi, K.; Wada, T.; et al. Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD. Clin. Exp. Nephrol. 2016, 20, 195–203. [Google Scholar] [CrossRef] [PubMed]
  66. Maeda, Y.; Suzuki, A.; Ishii, J.; Sekiguchi-Ueda, S.; Shibata, M.; Yoshino, Y.; Asano, S.; Hayakawa, N.; Nakamura, K.; Akiyama, Y.; et al. Level of urinary liver-type fatty acid-binding protein is associated with cardiac markers and electrocardiographic abnormalities in type-2 diabetes with chronic kidney disease stage G1 and G2. Heart Vessel. 2015, 30, 362–368. [Google Scholar] [CrossRef] [PubMed]
  67. Devuyst, O.; Olinger, E.; Rampoldi, L. Uromodulin: From physiology to rare and complex kidney disorders. Nat. Rev. Nephrol. 2017, 13, 525–544. [Google Scholar] [CrossRef]
  68. Fedak, D.; Kuźniewski, M.; Fugiel, A.; Wieczorek-Surdacka, E.; Przepiórkowska-Hoyer, B.; Jasik, P.; Miarka, P.; Dumnicka, P.; Kapusta, M.; Solnica, B.; et al. Serum uromodulin concentrations correlate with glomerular filtration rate in patients with chronic kidney disease. Pol. Arch. Med. Wewn. 2016, 126, 995–1004. [Google Scholar] [CrossRef] [Green Version]
  69. Steubl, D.; Block, M.; Herbst, V.; Nockher, W.A.; Schlumberger, W.; Satanovskij, R.; Angermann, S.; Hasenau, A.L.; Stecher, L.; Heemann, U.; et al. Plasma Uromodulin Correlates With Kidney Function and Identifies Early Stages in Chronic Kidney Disease Patients. Medicine 2016, 95, e3011. [Google Scholar] [CrossRef]
  70. Scherberich, J.E.; Gruber, R.; Nockher, W.A.; Christensen, E.I.; Schmitt, H.; Herbst, V.; Block, M.; Kaden, J.; Schlumberger, W. Serum uromodulin-a marker of kidney function and renal parenchymal integrity. Nephrol. Dial. Transplant. 2018, 33, 284–295. [Google Scholar] [CrossRef] [Green Version]
  71. Lim, W.H.; Lewis, J.R.; Wong, G.; Teo, R.; Lim, E.M.; Byrnes, E.; Prince, R.L. Plasma neutrophil gelatinase-associated lipocalin and kidney function decline and kidney disease-related clinical events in older women. Am. J. Nephrol. 2015, 41, 156–164. [Google Scholar] [CrossRef]
  72. Lv, L.; Wang, J.; Gao, B.; Wu, L.; Wang, F.; Cui, Z.; He, K.; Zhang, L.; Chen, M.; Zhao, M.H. Serum uromodulin and progression of kidney disease in patients with chronic kidney disease. J. Transl. Med. 2018, 16, 316. [Google Scholar] [CrossRef] [PubMed]
  73. Seibert, F.S.; Sitz, M.; Passfall, J.; Haesner, M.; Laschinski, P.; Buhl, M.; Bauer, F.; Babel, N.; Pagonas, N.; Westhoff, T.H. Prognostic Value of Urinary Calprotectin, NGAL and KIM-1 in Chronic Kidney Disease. Kidney Blood Press. Res. 2018, 43, 1255–1262. [Google Scholar] [CrossRef] [PubMed]
  74. Ding, Y.; Nie, L.M.; Pang, Y.; Wu, W.J.; Tan, Y.; Yu, F.; Zhao, M.H. Composite urinary biomarkers to predict pathological tubulointerstitial lesions in lupus nephritis. Lupus 2018, 27, 1778–1789. [Google Scholar] [CrossRef] [PubMed]
  75. Steubl, D.; Block, M.; Herbst, V.; Nockher, W.A.; Schlumberger, W.; Kemmner, S.; Bachmann, Q.; Angermann, S.; Wen, M.; Heemann, U.; et al. Urinary uromodulin independently predicts end-stage renal disease and rapid kidney function decline in a cohort of chronic kidney disease patients. Medicine 2019, 98, e15808. [Google Scholar] [CrossRef] [PubMed]
  76. Steubl, D.; Buzkova, P.; Garimella, P.S.; Ix, J.H.; Devarajan, P.; Bennett, M.R.; Chaves, P.H.M.; Shlipak, M.G.; Bansal, N.; Sarnak, M.J. Association of Serum Uromodulin With ESKD and Kidney Function Decline in the Elderly: The Cardiovascular Health Study. Am. J. Kidney Dis. 2019, 74, 501–509. [Google Scholar] [CrossRef] [PubMed]
  77. Plesiński, K.; Adamczyk, P.; Świętochowska, E.; Morawiec-Knysak, A.; Gliwińska, A.; Korlacki, W.; Szczepańska, M. Evaluation of liver-type fatty acid binding protein (L-FABP) and interleukin 6 in children with renal cysts. Adv. Clin. Exp. Med. 2019, 28, 1675–1682. [Google Scholar] [CrossRef] [PubMed]
  78. An, C.; Akankwasa, G.; Liu, J.; Wang, D.; Cheng, G.; Zhang, J.; Qin, X. Urine markers of renal tubular injury in idiopathic membranous nephropathy: A cross sectional study. Clin. Chim. Acta 2019, 492, 7–11. [Google Scholar] [CrossRef]
  79. Li, A.; Yi, B.; Liu, Y.; Wang, J.; Dai, Q.; Huang, Y.; Li, Y.C.; Zhang, H. Urinary NGAL and RBP Are Biomarkers of Normoalbuminuric Renal Insufficiency in Type 2 Diabetes Mellitus. J. Immunol. Res. 2019, 2019, 5063089. [Google Scholar] [CrossRef]
  80. Garimella, P.S.; Lee, A.K.; Ambrosius, W.T.; Bhatt, U.; Cheung, A.K.; Chonchol, M.; Craven, T.; Hawfield, A.T.; Jotwani, V.; Killeen, A.; et al. Markers of kidney tubule function and risk of cardiovascular disease events and mortality in the SPRINT trial. Eur. Heart J. 2019, 40, 3486–3493. [Google Scholar] [CrossRef]
  81. Zhang, D.; Ye, S.; Pan, T. The role of serum and urinary biomarkers in the diagnosis of early diabetic nephropathy in patients with type 2 diabetes. PeerJ 2019, 7, e7079. [Google Scholar] [CrossRef] [Green Version]
  82. Schulz, C.A.; Engström, G.; Nilsson, J.; Almgren, P.; Petkovic, M.; Christensson, A.; Nilsson, P.M.; Melander, O.; Orho-Melander, M. Plasma kidney injury molecule-1 (p-KIM-1) levels and deterioration of kidney function over 16 years. Nephrol. Dial. Transplant. 2020, 35, 265–273. [Google Scholar] [CrossRef] [PubMed]
  83. Malyszko, J. Mechanism of endothelial dysfunction in chronic kidney disease. Clin. Chim. Acta 2010, 411, 1412–1420. [Google Scholar] [CrossRef] [PubMed]
  84. Quoc Hoang, T.A.; Tam, V.; Thang, H.V. Plasma asymmetric dimethylarginine and its association with some of cardiovascular disease risk factors in chronic kidney disease. Med. J. Malays. 2019, 74, 209–214. [Google Scholar]
  85. Triches, C.B.; Quinto, M.; Mayer, S.; Batista, M.; Zanella, M.T. Relation of asymmetrical dimethylarginine levels with renal outcomes in hypertensive patients with and without type 2 diabetes mellitus. J. Diabetes Complicat. 2018, 32, 316–320. [Google Scholar] [CrossRef]
  86. Ashokachakkaravarthy, K.; Rajappa, M.; Parameswaran, S.; Satheesh, S.; Priyadarshini, G.; Mohan Raj, P.S.; Revathy, G.; Priyadarssini, M. Asymmetric dimethylarginine and angiopoietin-like protein-2 are independent predictors of cardiovascular risk in pre-dialysis non-diabetic chronic kidney disease patients. Int. Urol. Nephrol. 2020. [Google Scholar] [CrossRef]
  87. Martens, C.R.; Kirkman, D.L.; Edwards, D.G. The Vascular Endothelium in Chronic Kidney Disease: A Novel Target for Aerobic Exercise. Exerc. Sport Sci. Rev. 2016, 44, 12–19. [Google Scholar] [CrossRef] [Green Version]
  88. Moe, S.M.; Chen, N.X. Mechanisms of vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol. 2008, 19, 213–216. [Google Scholar] [CrossRef] [Green Version]
  89. Oliva-Damaso, E.; Oliva-Damaso, N.; Rodriguez-Esparragon, F.; Payan, J.; Baamonde-Laborda, E.; Gonzalez-Cabrera, F.; Santana-Estupiñan, R.; Rodriguez-Perez, J.C. Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach. Int. J. Mol. Sci. 2019, 20, 3668. [Google Scholar] [CrossRef] [Green Version]
  90. Schlesinger, S.; Sonntag, S.R.; Lieb, W.; Maas, R. Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Studies. PLoS ONE 2016, 11, e0165811. [Google Scholar] [CrossRef]
  91. Choi, H.R.; Lee, S.W.; Jeon, D.H.; Hur, N.W.; Youm, Y.; Kim, H.C. Association between estimated glomerular filtration rate (eGFR) and asymmetric dimethylarginine (ADMA) concentrations among the elderly in a rural community: A cross-sectional study. BMC Geriatr. 2019, 19, 370. [Google Scholar] [CrossRef] [Green Version]
  92. Wang, F.; Xiong, R.; Feng, S.; Lu, X.; Li, H.; Wang, S. Association of Circulating Levels of ADMA with Carotid Intima-Media Thickness in Patients with CKD: A Systematic Review and Meta-Analysis. Kidney Blood Press. Res. 2018, 43, 25–33. [Google Scholar] [CrossRef] [PubMed]
  93. Bartnicki, P.; Kowalczyk, M.; Franczyk-Skóra, B.; Baj, Z.; Rysz, J. Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease. Curr. Vasc. Pharmacol. 2016, 14, 360–367. [Google Scholar] [CrossRef] [PubMed]
  94. Seliger, S.L.; Salimi, S.; Pierre, V.; Giffuni, J.; Katzel, L.; Parsa, A. Microvascular endothelial dysfunction is associated with albuminuria and CKD in older adults. BMC Nephrol. 2016, 17, 82. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Caglar, K.; Yilmaz, M.I.; Saglam, M.; Cakir, E.; Kilic, S.; Sonmez, A.; Eyileten, T.; Yenicesu, M.; Oguz, Y.; Tasar, M.; et al. Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease. Nephron. Clin. Pract. 2008, 108, c233–c240. [Google Scholar] [CrossRef]
  96. Cozzolino, M.; Galassi, A.; Biondi, M.L.; Turri, O.; Papagni, S.; Mongelli, N.; Civita, L.; Gallieni, M.; Brancaccio, D. Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. Am. J. Nephrol. 2006, 26, 423–429. [Google Scholar] [CrossRef]
  97. Mutluay, R.; Konca Değertekin, C.; Işıktaş Sayılar, E.; Derici, Ü.; Gültekin, S.; Gönen, S.; Arınsoy, S.T.; Sindel, M. Serum fetuin-A is associated with the components of MIAC(malnutrition, inflammation, atherosclerosis, calcification) syndrome in different stages of chronic kidney disease. Turk. J. Med. Sci. 2019, 49, 327–335. [Google Scholar] [CrossRef]
  98. Zhou, Z.; Ji, Y.; Ju, H.; Chen, H.; Sun, M. Circulating Fetuin-A and Risk of All-Cause Mortality in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Front. Physiol. 2019, 10, 966. [Google Scholar] [CrossRef]
  99. Ciaccio, M.; Bivona, G.; Di Sciacca, R.; Iatrino, R.; Di Natale, E.; Li Vecchi, M.; Bellia, C. Changes in serum fetuin-A and inflammatory markers levels in end-stage renal disease (ESRD): Effect of a single session haemodialysis. Clin. Chem. Lab. Med. 2008, 46, 212–214. [Google Scholar] [CrossRef]
  100. Wang, A.Y.; Woo, J.; Lam, C.W.; Wang, M.; Chan, I.H.; Gao, P.; Lui, S.F.; Li, P.K.; Sanderson, J.E. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol. Dial. Transplant. 2005, 20, 1676–1685. [Google Scholar] [CrossRef] [Green Version]
  101. Pérez-Sotelo, D.; Roca-Rivada, A.; Larrosa-García, M.; Castelao, C.; Baamonde, I.; Baltar, J.; Crujeiras, A.B.; Seoane, L.M.; Casanueva, F.F.; Pardo, M. Visceral and subcutaneous adipose tissue express and secrete functional alpha2hsglycoprotein (fetuin a) especially in obesity. Endocrine 2017, 55, 435–446. [Google Scholar] [CrossRef]
  102. Zha, Y.; Qian, Q. Protein Nutrition and Malnutrition in CKD and ESRD. Nutrients 2017, 9, 208. [Google Scholar] [CrossRef]
  103. Iorember, F.M. Malnutrition in Chronic Kidney Disease. Front. Pediatr. 2018, 6, 161. [Google Scholar] [CrossRef] [PubMed]
  104. Chen, J.; Hamm, L.L.; Mohler, E.R.; Hudaihed, A.; Arora, R.; Chen, C.S.; Liu, Y.; Browne, G.; Mills, K.T.; Kleinpeter, M.A.; et al. Interrelationship of Multiple Endothelial Dysfunction Biomarkers with Chronic Kidney Disease. PLoS ONE 2015, 10, e0132047. [Google Scholar] [CrossRef] [Green Version]
  105. Kanbay, M.; Afsar, B.; Siriopol, D.; Unal, H.U.; Karaman, M.; Saglam, M.; Eyileten, T.; Gezer, M.; Verim, S.; Oguz, Y.; et al. Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients. Int. Urol. Nephrol. 2016, 48, 1129–1136. [Google Scholar] [CrossRef] [PubMed]
  106. Alderson, H.V.; Ritchie, J.P.; Middleton, R.; Larsson, A.; Larsson, T.E.; Kalra, P.A. FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5. Nephrology 2016, 21, 566–573. [Google Scholar] [CrossRef] [PubMed]
  107. Emrich, I.E.; Zawada, A.M.; Martens-Lobenhoffer, J.; Fliser, D.; Wagenpfeil, S.; Heine, G.H.; Bode-Böger, S.M. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease. Clin. Res. Cardiol. 2018, 107, 201–213. [Google Scholar] [CrossRef] [PubMed]
  108. Amdur, R.L.; Feldman, H.I.; Gupta, J.; Yang, W.; Kanetsky, P.; Shlipak, M.; Rahman, M.; Lash, J.P.; Townsend, R.R.; Ojo, A.; et al. Inflammation and Progression of CKD: The CRIC Study. Clin. J. Am. Soc. Nephrol. 2016, 11, 1546–1556. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  109. Gupta, J.; Mitra, N.; Kanetsky, P.A.; Devaney, J.; Wing, M.R.; Reilly, M.; Shah, V.O.; Balakrishnan, V.S.; Guzman, N.J.; Girndt, M.; et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin. J. Am. Soc. Nephrol. 2012, 7, 1938–1946. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  110. Mihai, S.; Codrici, E.; Popescu, I.D.; Enciu, A.-M.; Albulescu, L.; Necula, L.G.; Mambet, C.; Anton, G.; Tanase, C. Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome. J. Immunol. Res. 2018, 2018, 2180373. [Google Scholar] [CrossRef] [PubMed]
  111. Bash, L.D.; Erlinger, T.P.; Coresh, J.; Marsh-Manzi, J.; Folsom, A.R.; Astor, B.C. Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Kidney Dis. 2009, 53, 596–605. [Google Scholar] [CrossRef] [Green Version]
  112. Sun, J.; Axelsson, J.; Machowska, A.; Heimbürger, O.; Bárány, P.; Lindholm, B.; Lindström, K.; Stenvinkel, P.; Qureshi, A.R. Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD. Clin. J. Am. Soc. Nephrol. 2016, 11, 1163–1172. [Google Scholar] [CrossRef] [PubMed]
  113. Romanova, Y.; Laikov, A.; Markelova, M.; Khadiullina, R.; Makseev, A.; Hasanova, M.; Rizvanov, A.; Khaiboullina, S.; Salafutdinov, I. Proteomic Analysis of Human Serum from Patients with Chronic Kidney Disease. Biomolecules 2020, 10, 257. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  114. Kamińska, J.; Stopiński, M.; Mucha, K.; Jędrzejczak, A.; Gołębiowski, M.; Niewczas, M.A.; Pączek, L.; Foroncewicz, B. IL 6 but not TNF is linked to coronary artery calcification in patients with chronic kidney disease. Cytokine 2019, 120, 9–14. [Google Scholar] [CrossRef] [PubMed]
  115. Milas, O.; Gadalean, F.; Vlad, A.; Dumitrascu, V.; Velciov, S.; Gluhovschi, C.; Bob, F.; Popescu, R.; Ursoniu, S.; Jianu, D.C.; et al. Pro-inflammatory cytokines are associated with podocyte damage and proximal tubular dysfunction in the early stage of diabetic kidney disease in type 2 diabetes mellitus patients. J. Diabetes Complicat. 2020, 34, 107479. [Google Scholar] [CrossRef]
  116. Malhotra, R.; Katz, R.; Jotwani, V.; Ambrosius, W.T.; Raphael, K.L.; Haley, W.; Rastogi, A.; Cheung, A.K.; Freedman, B.I.; Punzi, H.; et al. Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKD. Clin. J. Am. Soc. Nephrol. 2020, 15, 349–358. [Google Scholar] [CrossRef]
  117. Bae, E.; Cha, R.H.; Kim, Y.C.; An, J.N.; Kim, D.K.; Yoo, K.D.; Lee, S.M.; Kim, M.H.; Park, J.T.; Kang, S.W.; et al. Circulating TNF receptors predict cardiovascular disease in patients with chronic kidney disease. Medicine 2017, 96, e6666. [Google Scholar] [CrossRef]
  118. Murakoshi, M.; Gohda, T.; Suzuki, Y. Circulating Tumor Necrosis Factor Receptors: A Potential Biomarker for the Progression of Diabetic Kidney Disease. Int. J. Mol. Sci. 2020, 21, 1957. [Google Scholar] [CrossRef] [Green Version]
  119. Tong, M.; Carrero, J.J.; Qureshi, A.R.; Anderstam, B.; Heimbürger, O.; Bárány, P.; Axelsson, J.; Alvestrand, A.; Stenvinkel, P.; Lindholm, B.; et al. Plasma pentraxin 3 in patients with chronic kidney disease: Associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin. J. Am. Soc. Nephrol. 2007, 2, 889–897. [Google Scholar] [CrossRef] [Green Version]
  120. Speeckaert, M.M.; Speeckaert, R.; Carrero, J.J.; Vanholder, R.; Delanghe, J.R. Biology of human pentraxin 3 (PTX3) in acute and chronic kidney disease. J. Clin. Immunol. 2013, 33, 881–890. [Google Scholar] [CrossRef]
  121. Sjöberg, B.; Qureshi, A.R.; Heimbürger, O.; Stenvinkel, P.; Lind, L.; Larsson, A.; Bárány, P.; Ärnlöv, J. Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly. J. Intern. Med. 2016, 279, 173–179. [Google Scholar] [CrossRef] [Green Version]
  122. Valente, M.J.; Rocha, S.; Coimbra, S.; Catarino, C.; Rocha-Pereira, P.; Bronze-da-Rocha, E.; Oliveira, J.G.; Madureira, J.; Fernandes, J.C.; do Sameiro-Faria, M.; et al. Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality. Mediat. Inflamm. 2019, 2019, 3295725. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  123. Krzanowski, M.; Krzanowska, K.; Gajda, M.; Dumnicka, P.; Dziewierz, A.; Woziwodzka, K.; Litwin, J.A.; Sułowicz, W. Pentraxin 3 as a new indicator of cardiovascular-related death in patients with advanced chronic kidney disease. Pol. Arch. Intern. Med. 2017, 127, 170–177. [Google Scholar] [CrossRef] [PubMed]
  124. Nair, V.; Robinson-Cohen, C.; Smith, M.R.; Bellovich, K.A.; Bhat, Z.Y.; Bobadilla, M.; Brosius, F.; de Boer, I.H.; Essioux, L.; Formentini, I.; et al. Growth Differentiation Factor-15 and Risk of CKD Progression. J. Am. Soc. Nephrol. 2017, 28, 2233–2240. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  125. Bansal, N.; Zelnick, L.; Shlipak, M.G.; Anderson, A.; Christenson, R.; Deo, R.; deFilippi, C.; Feldman, H.; Lash, J.; He, J.; et al. Cardiac and Stress Biomarkers and Chronic Kidney Disease Progression: The CRIC Study. Clin. Chem. 2019, 65, 1448–1457. [Google Scholar] [CrossRef]
  126. Tuegel, C.; Katz, R.; Alam, M.; Bhat, Z.; Bellovich, K.; de Boer, I.; Brosius, F.; Gadegbeku, C.; Gipson, D.; Hawkins, J.; et al. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. Am. J. Kidney Dis. 2018, 72, 519–528. [Google Scholar] [CrossRef]
  127. Mirna, M.; Topf, A.; Wernly, B.; Rezar, R.; Paar, V.; Jung, C.; Salmhofer, H.; Kopp, K.; Hoppe, U.C.; Schulze, P.C.; et al. Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study. J. Clin. Med. 2020, 9, 886. [Google Scholar] [CrossRef] [Green Version]
  128. Ho, J.E.; Hwang, S.J.; Wollert, K.C.; Larson, M.G.; Cheng, S.; Kempf, T.; Vasan, R.S.; Januzzi, J.L.; Wang, T.J.; Fox, C.S. Biomarkers of cardiovascular stress and incident chronic kidney disease. Clin. Chem. 2013, 59, 1613–1620. [Google Scholar] [CrossRef] [Green Version]
  129. Celec, P.; Vlková, B.; Lauková, L.; Bábíčková, J.; Boor, P. Cell-free DNA: The role in pathophysiology and as a biomarker in kidney diseases. Expert Rev. Mol. Med. 2018, 20, e1. [Google Scholar] [CrossRef]
  130. Nuzzo, P.V.; Berchuck, J.E.; Korthauer, K.; Spisak, S.; Nassar, A.H.; Abou Alaiwi, S.; Chakravarthy, A.; Shen, S.Y.; Bakouny, Z.; Boccardo, F.; et al. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat. Med. 2020. [Google Scholar] [CrossRef]
  131. Merkle, J.; Daka, A.; Deppe, A.C.; Wahlers, T.; Paunel-Görgülü, A. High levels of cell-free DNA accurately predict late acute kidney injury in patients after cardiac surgery. PLoS ONE 2019, 14, e0218548. [Google Scholar] [CrossRef]
  132. Coimbra, S.; Santos-Silva, A.; Costa, E.; Bronze-da-Rocha, E. DNA Damage in End-Stage Renal Disease Patients. Assessment by In Vitro Comet Assay and by Cell-Free DNA Quantification. In Genotoxicity—A Predictable Risk to Our Actual World; Larramendy, L.M., Soloneski, S., Eds.; Intech, Open Access Publisher: London, UK, 2017. [Google Scholar] [CrossRef] [Green Version]
  133. Chang, C.C.; Chiu, P.F.; Wu, C.L.; Kuo, C.L.; Huang, C.S.; Liu, C.S.; Huang, C.H. Urinary cell-free mitochondrial and nuclear deoxyribonucleic acid correlates with the prognosis of chronic kidney diseases. BMC Nephrol. 2019, 20, 391. [Google Scholar] [CrossRef] [PubMed]
  134. Li, X.; Hu, R.; Luo, T.; Peng, C.; Gong, L.; Hu, J.; Yang, S.; Li, Q. Serum cell-free DNA and progression of diabetic kidney disease: A prospective study. BMJ Open Diabetes Res. Care 2020, 8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  135. Watson, D.; Yang, J.Y.C.; Sarwal, R.D.; Sigdel, T.K.; Liberto, J.M.; Damm, I.; Louie, V.; Sigdel, S.; Livingstone, D.; Soh, K.; et al. A Novel Multi-Biomarker Assay for Non-Invasive Quantitative Monitoring of Kidney Injury. J. Clin. Med. 2019, 8, 499. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  136. Lee, R.; Shin, M.H.; Kim, H.N.; Lee, Y.H.; Choi, S.W.; Ahn, H.R.; Kweon, S.S. Relationship between plasma pentraxin 3 level and risk of chronic kidney disease in the Korean elderly: The Dong-gu study. Int. Urol. Nephrol. 2017, 49, 2027–2033. [Google Scholar] [CrossRef]
  137. Frimodt-Møller, M.; von Scholten, B.J.; Reinhard, H.; Jacobsen, P.K.; Hansen, T.W.; Persson, F.I.; Parving, H.H.; Rossing, P. Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes—An observational follow-up study. PLoS ONE 2018, 13, e0196634. [Google Scholar] [CrossRef] [Green Version]
  138. Anderson, C.E.; Hamm, L.L.; Batuman, G.; Kumbala, D.R.; Chen, C.S.; Kallu, S.G.; Siriki, R.; Gadde, S.; Kleinpeter, M.A.; Krane, N.K.; et al. The association of angiogenic factors and chronic kidney disease. BMC Nephrol. 2018, 19, 117. [Google Scholar] [CrossRef] [Green Version]
  139. Lee, J.; Choi, J.Y.; Kwon, Y.K.; Lee, D.; Jung, H.Y.; Ryu, H.M.; Cho, J.H.; Ryu, D.H.; Kim, Y.L.; Hwang, G.S. Changes in serum metabolites with the stage of chronic kidney disease: Comparison of diabetes and non-diabetes. Clin. Chim. Acta 2016, 459, 123–131. [Google Scholar] [CrossRef]
  140. McMahon, G.M.; Hwang, S.J.; Clish, C.B.; Tin, A.; Yang, Q.; Larson, M.G.; Rhee, E.P.; Li, M.; Levy, D.; O’Donnell, C.J.; et al. Urinary metabolites along with common and rare genetic variations are associated with incident chronic kidney disease. Kidney Int. 2017, 91, 1426–1435. [Google Scholar] [CrossRef]
  141. Guo, Y.; Yu, H.; Chen, D.; Zhao, Y.Y. Machine learning distilled metabolite biomarkers for early stage renal injury. Metabolomics 2019, 16, 4. [Google Scholar] [CrossRef]
  142. Lee, H.; Jang, H.B.; Yoo, M.G.; Park, S.I.; Lee, H.J. Amino Acid Metabolites Associated with Chronic Kidney Disease: An Eight-Year Follow-Up Korean Epidemiology Study. Biomedicines 2020, 8, 222. [Google Scholar] [CrossRef]
  143. Konje, V.C.; Rajendiran, T.M.; Bellovich, K.; Gadegbeku, C.A.; Gipson, D.S.; Afshinnia, F.; Mathew, A.V.; Michigan Kidney Translational Core CPROBE Investigator Group. Tryptophan levels associate with incident cardiovascular disease in chronic kidney disease. Clin. Kidney J. 2020. [Google Scholar] [CrossRef]
  144. Debnath, S.; Velagapudi, C.; Redus, L.; Thameem, F.; Kasinath, B.; Hura, C.E.; Lorenzo, C.; Abboud, H.E.; O’Connor, J.C. Tryptophan Metabolism in Patients With Chronic Kidney Disease Secondary to Type 2 Diabetes: Relationship to Inflammatory Markers. Int. J. Tryptophan Res. 2017, 10, 1178646917694600. [Google Scholar] [CrossRef] [PubMed]
  145. Ma, J.; Karnovsky, A.; Afshinnia, F.; Wigginton, J.; Rader, D.J.; Natarajan, L.; Sharma, K.; Porter, A.C.; Rahman, M.; He, J.; et al. Differential network enrichment analysis reveals novel lipid pathways in chronic kidney disease. Bioinformatics 2019, 35, 3441–3452. [Google Scholar] [CrossRef] [PubMed]
  146. Hu, J.-R.; Coresh, J.; Inker, L.A.; Levey, A.S.; Zheng, Z.; Rebholz, C.M.; Tin, A.; Appel, L.J.; Chen, J.; Sarnak, M.J.; et al. Serum metabolites are associated with all-cause mortality in chronic kidney disease. Kidney Int. 2018, 94, 381–389. [Google Scholar] [CrossRef] [PubMed]
  147. Grams, M.E.; Tin, A.; Rebholz, C.M.; Shafi, T.; Köttgen, A.; Perrone, R.D.; Sarnak, M.J.; Inker, L.A.; Levey, A.S.; Coresh, J. Metabolomic Alterations Associated with Cause of CKD. Clin. J. Am. Soc. Nephrol. 2017, 12, 1787–1794. [Google Scholar] [CrossRef] [PubMed]
  148. Tavares, G.; Venturini, G.; Padilha, K.; Zatz, R.; Pereira, A.C.; Thadhani, R.I.; Rhee, E.P.; Titan, S.M.O. 1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: Results from non-targeted metabolomics. Metabolomics 2018, 14, 39. [Google Scholar] [CrossRef] [PubMed]
  149. Luo, S.; Coresh, J.; Tin, A.; Rebholz, C.M.; Appel, L.J.; Chen, J.; Vasan, R.S.; Anderson, A.H.; Feldman, H.I.; Kimmel, P.L.; et al. Serum Metabolomic Alterations Associated with Proteinuria in CKD. Clin. J. Am. Soc. Nephrol. 2019, 14, 342–353. [Google Scholar] [CrossRef] [Green Version]
  150. Hallan, S.; Afkarian, M.; Zelnick, L.R.; Kestenbaum, B.; Sharma, S.; Saito, R.; Darshi, M.; Barding, G.; Raftery, D.; Ju, W.; et al. Metabolomics and Gene Expression Analysis Reveal Down-regulation of the Citric Acid (TCA) Cycle in Non-diabetic CKD Patients. EBioMedicine 2017, 26, 68–77. [Google Scholar] [CrossRef] [Green Version]
  151. Hocher, B.; Adamski, J. Metabolomics for clinical use and research in chronic kidney disease. Nat. Rev. Nephrol. 2017, 13, 269–284. [Google Scholar] [CrossRef]
  152. Cañadas-Garre, M.; Anderson, K.; McGoldrick, J.; Maxwell, A.P.; McKnight, A.J. Proteomic and metabolomic approaches in the search for biomarkers in chronic kidney disease. J. Proteom. 2019, 193, 93–122. [Google Scholar] [CrossRef] [Green Version]
  153. Good, D.M.; Zürbig, P.; Argilés, A.; Bauer, H.W.; Behrens, G.; Coon, J.J.; Dakna, M.; Decramer, S.; Delles, C.; Dominiczak, A.F.; et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol. Cell Proteom. 2010, 9, 2424–2437. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  154. Pontillo, C.; Mischak, H. Urinary peptide-based classifier CKD273: Towards clinical application in chronic kidney disease. Clin. Kidney J. 2017, 10, 192–201. [Google Scholar] [CrossRef] [PubMed]
  155. Tofte, N.; Lindhardt, M.; Adamova, K.; Bakker, S.J.L.; Beige, J.; Beulens, J.W.J.; Birkenfeld, A.L.; Currie, G.; Delles, C.; Dimos, I.; et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): A prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 2020, 8, 301–312. [Google Scholar] [CrossRef]
  156. Karu, N.; McKercher, C.; Nichols, D.S.; Davies, N.; Shellie, R.A.; Hilder, E.F.; Jose, M.D. Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian Chronic Kidney Disease pilot study. BMC Nephrol. 2016, 17, 171. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  157. Kimura, T.; Yasuda, K.; Yamamoto, R.; Soga, T.; Rakugi, H.; Hayashi, T.; Isaka, Y. Identification of biomarkers for development of end-stage kidney disease in chronic kidney disease by metabolomic profiling. Sci. Rep. 2016, 6, 26138. [Google Scholar] [CrossRef]
  158. Rhee, E.P.; Clish, C.B.; Wenger, J.; Roy, J.; Elmariah, S.; Pierce, K.A.; Bullock, K.; Anderson, A.H.; Gerszten, R.E.; Feldman, H.I. Metabolomics of Chronic Kidney Disease Progression: A Case-Control Analysis in the Chronic Renal Insufficiency Cohort Study. Am. J. Nephrol. 2016, 43, 366–374. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  159. Sekula, P.; Goek, O.N.; Quaye, L.; Barrios, C.; Levey, A.S.; Römisch-Margl, W.; Menni, C.; Yet, I.; Gieger, C.; Inker, L.A.; et al. A Metabolome-Wide Association Study of Kidney Function and Disease in the General Population. J. Am. Soc. Nephrol. 2016, 27, 1175–1188. [Google Scholar] [CrossRef]
  160. Boelaert, J.; Lynen, F.; Glorieux, G.; Schepers, E.; Neirynck, N.; Vanholder, R. Metabolic profiling of human plasma and urine in chronic kidney disease by hydrophilic interaction liquid chromatography coupled with time-of-flight mass spectrometry: A pilot study. Anal. Bioanal. Chem. 2017, 409, 2201–2211. [Google Scholar] [CrossRef] [Green Version]
  161. Gil, R.B.; Ortiz, A.; Sanchez-Niño, M.D.; Markoska, K.; Schepers, E.; Vanholder, R.; Glorieux, G.; Schmitt-Kopplin, P.; Heinzmann, S.S. Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate. Nephrol. Dial. Transplant. 2018, 33, 2156–2164. [Google Scholar] [CrossRef]
  162. Wang, F.; Sun, L.; Sun, Q.; Liang, L.; Gao, X.; Li, R.; Pan, A.; Li, H.; Deng, Y.; Hu, F.B.; et al. Associations of Plasma Amino Acid and Acylcarnitine Profiles with Incident Reduced Glomerular Filtration Rate. Clin. J. Am. Soc. Nephrol. 2018, 13, 560–568. [Google Scholar] [CrossRef] [Green Version]
  163. Kordalewska, M.; Macioszek, S.; Wawrzyniak, R.; Sikorska-Wiśniewska, M.; Śledziński, T.; Chmielewski, M.; Mika, A.; Markuszewski, M.J. Multiplatform metabolomics provides insight into the molecular basis of chronic kidney disease. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2019, 1117, 49–57. [Google Scholar] [CrossRef] [PubMed]
  164. Nierenberg, J.L.; He, J.; Li, C.; Gu, X.; Shi, M.; Razavi, A.C.; Mi, X.; Li, S.; Bazzano, L.A.; Anderson, A.H.; et al. Novel associations between blood metabolites and kidney function among Bogalusa Heart Study and Multi-Ethnic Study of Atherosclerosis participants. Metabolomics 2019, 15, 149. [Google Scholar] [CrossRef] [PubMed]
  165. Titan, S.M.; Venturini, G.; Padilha, K.; Goulart, A.C.; Lotufo, P.A.; Bensenor, I.J.; Krieger, J.E.; Thadhani, R.I.; Rhee, E.P.; Pereira, A.C. Metabolomics biomarkers and the risk of overall mortality and ESRD in CKD: Results from the Progredir Cohort. PLoS ONE 2019, 14, e0213764. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  166. Sun, C.Y.; Lin, C.J.; Pan, H.C.; Lee, C.C.; Lu, S.C.; Hsieh, Y.T.; Huang, S.Y.; Huang, H.Y. Clinical association between the metabolite of healthy gut microbiota, 3-indolepropionic acid and chronic kidney disease. Clin. Nutr. 2019, 38, 2945–2948. [Google Scholar] [CrossRef]
  167. Dekker, S.E.I.; Verhoeven, A.; Soonawala, D.; Peters, D.J.M.; de Fijter, J.W.; Mayboroda, O.A. Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease. PLoS ONE 2020, 15, e0233213. [Google Scholar] [CrossRef]
  168. Levey, A.S.; Perrone, R.D.; Madias, N.E. Serum Creatinine and Renal Function. Annu. Rev. Med. 1988, 39, 465–490. [Google Scholar] [CrossRef]
  169. Ichii, O.; Horino, T. MicroRNAs associated with the development of kidney diseases in humans and animals. J. Toxicol. Pathol. 2018, 31, 23–34. [Google Scholar] [CrossRef] [Green Version]
  170. Metzinger-Le Meuth, V.; Burtey, S.; Maitrias, P.; Massy, Z.A.; Metzinger, L. microRNAs in the pathophysiology of CKD-MBD: Biomarkers and innovative drugs. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 337–345. [Google Scholar] [CrossRef]
  171. Shang, F.; Wang, S.C.; Hsu, C.Y.; Miao, Y.; Martin, M.; Yin, Y.; Wu, C.C.; Wang, Y.T.; Wu, G.; Chien, S.; et al. MicroRNA-92a Mediates Endothelial Dysfunction in CKD. J. Am. Soc. Nephrol. 2017, 28, 3251–3261. [Google Scholar] [CrossRef] [Green Version]
  172. Lv, W.; Fan, F.; Wang, Y.; Gonzalez-Fernandez, E.; Wang, C.; Yang, L.; Booz, G.W.; Roman, R.J. Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD. Physiol. Genom. 2018, 50, 20–34. [Google Scholar] [CrossRef]
  173. Peters, L.J.F.; Floege, J.; Biessen, E.A.L.; Jankowski, J.; van der Vorst, E.P.C. MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application. Int. J. Mol. Sci. 2020, 21, 6547. [Google Scholar] [CrossRef] [PubMed]
  174. Hsu, C.Y.; Ballard, S.; Batlle, D.; Bonventre, J.V.; Bottinger, E.P.; Feldman, H.I.; Klein, J.B.; Coresh, J.; Eckfeldt, J.H.; Inker, L.A.; et al. Cross-Disciplinary Biomarkers Research: Lessons Learned by the CKD Biomarkers Consortium. Clin. J. Am. Soc. Nephrol. 2015, 10, 894–902. [Google Scholar] [CrossRef] [PubMed]
Ijms 22 00043 g001 550
Figure 1. Mechanisms and related consequences of tubular cells activation, triggered by tubular and glomerular injuries.
Figure 1. Mechanisms and related consequences of tubular cells activation, triggered by tubular and glomerular injuries.
Ijms 22 00043 g001
Ijms 22 00043 g002 550
Figure 2. Biomarkers of chronic kidney disease according to the anatomic localization and/or site of production.
Figure 2. Biomarkers of chronic kidney disease according to the anatomic localization and/or site of production.
Ijms 22 00043 g002
Table
Table 1. Research studies on biomarkers of renal function and main outcomes in CKD patients.
Table 1. Research studies on biomarkers of renal function and main outcomes in CKD patients.
YearStudy TypeStudy PopulationBiomarker (s)Study OutcomesReference
2015Prospective cohort9703 participants from the ARICserum B2MGreater than 30% decline in B2M may be less common, but appears to be more specific for ESRD than equivalent changes in eGFR based on serum creatinine[24]
2015Prospective cohort250 Pima Indians with T2Dserum BTP, B2MBTP and to a lesser extent B2M were associated with ESRD; only higher serum concentrations of B2M were associated with increased mortality risk in this population[22]
2015Cross-sectional93 CKD patients at stages 1–5urinary klothoDecreased tubular phosphate reabsorption was associated with decreased eGFR, but it was not associated with urinary klotho levels[39]
2016Cross-sectional355 CKD patients, classified in the different stages of CKDurinary BTPBTP is present in the urine of patients with normal GFR, and its urinary excretion progressively increases along with the reduction of GFR; clearance of BTP progressively increases with the reduction of GFR[16]
2016Cross-sectional109 CKD patients with T2D and 32 healthy controlsserum klothoSerum klotho levels were significantly elevated in diabetic patients; klotho levels decreased with increasing albumin excretion[33]
2016Retrospective cohort3551 participants with CKD from MDRD, AASK and CRIC studiesserum BTP, B2MBTP and B2M are less influenced by age, sex and race than creatinine and less influenced by race than cystatin C, but provide less accurate GFR estimates[10]
2016Prospective cohort3613 adults from the CRIC studyserum BTP, B2MBTP and B2M were independent predictors of ESRD and all-cause mortality, but only B2M was an independent predictor cardiovascular events[40]
2017Prospective cohort2496 participants from the Health Aging and Body Composition studyserum klothoHigher klotho levels were associated with lower odds of kidney function decline, but not with incident CKD[41]
2017Cross-sectional50 individuals with type 2 diabetes and 25 healthy controlsserum BTPBTP level was significantly higher in T2Dwith the microalbuminuria group than T2DM with normoalbuminuria and control groups[18]
2017Cross-sectional566 individuals aged 70+ from the Berlin Initiative Studyserum BTPCombination of creatinine, cystatin C and BTP showed the best prediction of GFR; single usage of BTP showed the worst prediction within models with only one biomarker[42]
2017Prospective cohort317 participants from MDRD and 373 from AASKserum BTP, B2MDeclines in eGFR based on the average of four filtration markers (creatinine, cystatin C, BTP, and B2M) were consistently associated with progression to ESRD; only the decline in eGFR-BTP was significantly more strongly associated with ESRD risk[23]
2017Meta-analysis23,318 individuals from six different studiesserum BTP, B2MeGFR-BTP, eGFR-B2M, and their average showed stronger risk associations with ESRD and all-cause mortality when compared with eGFRcr[27]
2017Cross-sectionalElderly participants from the AGES-Kidney study (683) and the MESA-Kidney (273)serum BTP, B2MeGFR-cys, eGFR-B2M and eGFR-BTP had significantly less strong residual associations with age and sex than eGFRcr[11]
2018Cross-sectional125 maintenance hemodialysis patientsserum klothoKlotho levels were associated with the degree of bone mineral density; osteoporosis groups presented lower levels than the normal bone mass group[37]
2018Prospective cohort112 adults with stages 1–5 CKDserum klothoKlotho levels were positively associated with baseline eGFR; reduction in klotho levels was associated with renal function decline[31]
2018Cross-sectional150 patients with CKD at stages 1–4 and 50 healthy controlsserum BTPIncreased BTP concentrations in CKD patients are highly significantly correlated with the concentrations of Cr and Cys; BTP had a higher value of correlation with mGFR[17]
2018Systematic review and meta-analysis9 publications, comprising 1457 CKD patientsserum klothoThere was a positive correlation between serum klotho levels and eGFR; no significant correlations were found between serum klotho levels and calcium and phosphorus circulating levels[32]
2018Cross-sectional566 individuals aged 70+ from the Berlin Initiative Studyserum BTPThe addition of BTP to serum creatinine-based eGFR equations does not result in the same improvement as the addition of Cys[25]
2018Cross-sectional50 healthy term neonatesserum BTPBTP concentrations were positively associated with the concentrations of serum Cr level; inverse serum BTP is associated with estimated GFR level among neonates[43]
2019Prospective cohort86 adults with stable CKDserum BTP, B2MThe addition of BTP/B2M eGFR to Cr/cysC eGFR equations did not improve GFR estimation[26]
2019Systematic Review and Meta-analysis8 cohort studies with 3586 participantsserum klothoKlotho levels were positively correlated with the eGFR; lower klotho levels were significantly associated with an increased risk of poor kidney outcomes[44]
2019Prospective cohort107 diabetic patients with CKD at stages 2 and 3serum klothoLower levels of klotho were associated with cardiac pathological changes and higher CVD risk[34]
2019Prospective cohort79 CKD patients on hemodialysisserum klothoLower klotho levels were associated with the risk of CVD, independently from factors associated with mineral bone disease[35]
2019Cross-sectional286 CKD patients at stages 2–5 serum klothoThe serum levels of inflammatory markers were negatively associated with klotho levels[36]
2019Cross-sectional152 patients with CKD at stages 3–5 and 30 healthy controlsserum klothoeGFR reduction was associated with decreased klotho levels; serum phosphate levels were negatively associated with klotho levels[38]
2020Cross-sectional1066 participants with Cr and Cys and 666 with all 4 markersserum BTP, B2MeGFR-B2M and eGFR-BTP were not more accurate than eGFR-cr and eGFR-cys; accuracy was significantly better for the eGFR equation considering the four markers when compared to eGFRcr-cys equation[15]
2020Prospective cohort 830 Chinese CKD patientsserum B2MThe B2M equation had smaller bias in the subgroup of GFR 60–89 mL/min/1.73 m2, but a larger bias and worse precision and accuracy in the subgroup of GFR > 90 mL/min/1.73 m2 when compared to the CKD-EPI equation[45]
2020Cross-sectional1793 patients from the KNOW-CKD studyserum klothoDecreased klotho levels correlated negatively with phosphate levels and with the degree of proteinuria[46]
Abbreviations: AASK, African American Study of Kidney Disease and Hypertension; AGES, Age, Gene/Environment Susceptibility; ARIC, Atherosclerosis Risk in Communities; B2M, beta-2 microglobulin; BTP, beta trace protein; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Cr, creatinine; CRIC, Chronic Renal Insufficiency Cohort; CVD, Cardiovascular disease; Cys, cystatin C; eGFR, estimated glomerular filtration rate; ESRD, End-stage renal disease MDRD, Modification of Diet in Renal Disease; MESA, Multi-Ethnic Study of Atherosclerosis; mGFR, measured glomerular filtration rate; T2D, type 2 diabetes.
Table
Table 2. Research studies on biomarkers of renal tubular lesions and main outcomes in CKD patients.
Table 2. Research studies on biomarkers of renal tubular lesions and main outcomes in CKD patients.
YearStudy TypeStudy PopulationBiomarker (s)Study OutcomesReference
2015Prospective cohort1245 women aged ≥ 70 from the general populationplasma NGALNGAL is of modest clinical utility in predicting renal function decline and acute or chronic renal disease-related events in individuals with mild-to-moderate CKD[71]
2015Cross-sectional276 type 2 diabetic patients with CKD at stage 1 and 2urinary L-FABPUrinary L-FABP was significantly correlated with UACR in the early stages of CKD[66]
2015Prospective cohort138 patients with CHFurinary KIM-1, NGAL, NAGIn patients with CKD progression, KIM-1 and NAG were elevated in contrast to NGAL; KIM-1 and NAG were negatively correlated with ejection fraction and eGFR[58]
2016Cross-sectional355 patients with CKD at stages 1–5 and 71 patients without CKDplasma and urinary UMODUMOD allowed the identification of patients without CKD and patients at any stage of CKD;
Plasma UMOD appears to outperform urinary uromodulin as a CKD marker		[69]
2016Prospective cohort244 adult patients with CKDurinary NAG,
L-FABP		Elevated urinary L-FABP and low eGFR were associated with the development of ESRD and CVD, irrespective of diabetes[65]
2016Cross-sectional170 patients with CKD at stages 1 to 5 and 30 healthy individualsserum UMODSerum UMOD concentrations in CKD patients were lower than in healthy subjects, and the lower concentrations were associated with more advanced stages[68]
2017Case–control74 adult CKD patients (stages 3–5) and 25 healthy subjectsurinary L-FABPL-FABP shows a negative correlation with GFR and a positive correlation with UAC; in patients without albuminuria, L-FABP was associated with renal function decline[64]
2017Prospective cohort250 patients with CKD at stages 1–5, including 111 on hemodialysisurinary KIM-1, NGAL, NAGNGAL was moderately correlated with the 5 stages of CKD, while KIM-1 and NAG were also correlated, but weakly[59]
2018Cross-sectional80 patients with T2D without significant decrease in eGFR and albuminuriaurinary NGAL, KIM-1, UMODUrinary NGAL and KIM-1 correlated positively with albuminuria; all markers differed significantly between patients with moderately increased albuminuria compared to those with normal to mildly increased albuminuria[55]
2018Prospective cohort2813 patients from C-STRIDE studyserum UMODHigher incidence rates of ESRD, CVD and death were associated with decreased UMOD levels[72]
2018Cross-sectional132 patients with CKD at stages 1–5 and 33 patients without CKDserum UMODUMOD levels inversely correlated with creatinine and creatinine/cystatin C-based eGFR[70]
2018Case–control324 participants from the SPRINT trial (162 who developed CKD during the follow-up and 162 matched controls)urinary KIM-1, NGAL, UMODOnly baseline concentrations of KIM-1 were associated with the development of incident CKD during the follow-up[54]
2018Prospective cohort527 adults with type 1 diabetes from the CACTI studyplasma KIM-1, NGAL, UMODNGAL and UMOD were associated with UACR and incident impaired GFR over the 12-year follow-up period[56]
2018Prospective cohort143 patients with stable CKD with diverse etiologiesurinary NGAL, KIM-1Neither NGAL nor KIM-1 provided robust prognostic information on the loss or renal function in a heterogeneous CKD population[73]
2018Cross-sectional109 biopsy-proven lupus nephritis patients and 50 healthy individualsurinary NGAL, KIM-1Patients with active lupus nephritis exhibited elevated urinary levels of KIM-1 and NGAL compared with patients in remission and controls; KIM-1 levels correlated with tubular atrophy and interstitial inflammatory lesions[74]
2019Prospective cohort230 CKD patients stages 1 to 5urinary UMODUMOD concentrations were positively associated with eGFR and inversely associated with proteinuria; UMOD levels were independently associated with ESRD or rapid loss of eGFR[75]
2019Prospective cohort933 individuals aged ≥65 years from the CHS studyserum UMODLower UMOD was associated with the development of ESRD independently of eGFR, UACR, and cardiovascular and CKD risk factors[76]
2019Cross-sectional39 children with kidney cysts, including 20 subjects with ADPKD, and 20 controlsurinary and serum L-FABPHigher concentration of L-FABP in serum and urine indicated early damage to the renal parenchyma, detectable before the onset of hypertension and other organ damage[77]
2019Cross-sectional165 biopsy-proven CKD patients and 64 healthy controlsurinary NAG, KIM-1, NGALAll biomarkers were significantly increased in patients, but their values were similar for patients with moderate and severe tubular injury[78]
2019Systematic review and meta-analysis22 studies involving 683 healthy individuals and 3249 diabetic patientsserum and urinary NGALBoth urinary and serum NGAL showed an increasing trend, in parallel with albuminuria and progression of the disease, estimated by eGFR; the highest concentrations were achieved in patients with the highest severity of diabetic nephropathy[52]
2019Cross-sectional209 T2D normoalbuminuric patients with or without CKDurinary NGALLevels of urinary NGAL were elevated in patients with renal insufficiency and negatively related to eGFR in T2D patients with normoalbuminuria[79]
2019Prospective cohort2377 participants from SPRINT trial with non-diabetic CKDurinary UMODLower uromodulin levels were associated with higher risk of CVD events and mortality, independently of eGFR, UACR, and other risk factors[80]
2019Cross-sectional287 T2D patients and 42 healthy controlsurinary NGALUrinary NGAL was significantly correlated with the UACR in patients with T2D[81]
2020Cross-sectional133 patients with diabetes and 39 healthy controlsurinary NGALPatients with severely increased albuminuria had higher levels of NGAL compared to patients with normal albuminuria and controls[51]
2020Prospective cohort4739 participants of the population-based Malmö Diet and Cancer Studyplasma KIM-1Plasma KIM-1 was able to predict the future decline of eGFR and the risk of CKD in healthy participants[82]
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; CACTI, Coronary Artery Calcification in Type 1 Diabetes study; CHF, congestive heart failure; CHS, Cardiovascular Health Study; CKD, chronic kidney disease; C-STRIDE, Chinese Cohort Study of Chronic Kidney Disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; KIM-1, kidney injury molecule-1; L-FABP, liver-type fatty acid binding protein; NAG, N-acetyl-β-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; SPRINT, Systolic Blood Pressure Intervention Trial; T2D, type 2 diabetes; UACR, urine albumin-to-creatinine ratio; UMOD, uromodulin.
Table
Table 3. Research studies on biomarkers of endothelial dysfunction and main outcomes in CKD patients.
Table 3. Research studies on biomarkers of endothelial dysfunction and main outcomes in CKD patients.
YearStudy TypeStudy PopulationBiomarker (s)Study OutcomesReference
2015Cross-sectional201 patients with CKD and 201 controlsplasma ADMAPlasma ADMA levels were associated with CKD severity measured by eGFR and/or albuminuria[104]
2016Prospective cohort259 patients with CKD at stages 1–5serum ADMAPatients with ADMA levels above the median value had an increased risk of all-cause mortality and CVE [105]
2016Cross-sectional35 pre-dialysis CKD patients, 40 on hemodialysis, and 15 healthy subjectsplasma ADMAPlasma ADMA concentration was associated with disadvantageous changes in left ventricular structure and function[93]
2016Prospective cohort463 individuals with CKD at stages 3–5 from the CRISIS Studyplasma fetuin-AThere was no clear association between fetuin-A and risk for RRT, CVE, and death[106]
2018Prospective cohort528 adult CKD patients at stages 2–4plasma ADMAeGFR was inversely correlated with plasma levels of ADMA[107]
2018Systematic review and meta-analysis6 articles, involving 616 CKD patientsplasma ADMALevels of circulating ADMA were positively related to CIMT in CKD patients[92]
2018Prospective cohort162 hypertensive CKD patients, free from albuminuriaplasma ADMAHigh ADMA levels were associated with the progression of albuminuria in hypertensive patients, with and without type 2 diabetes[85]
2019Cross-sectional651 elderly subjects from KSHAP cohort studyplasma ADMAeGFR levels were inversely associated with ADMA concentrations[91]
2019Cross-sectional176 CKD patients and 64 control subjectsplasma ADMAPlasma ADMA levels were similar in the control group and stage 1 CKD patients; in other stages, ADMA levels were significantly higher in comparison to the control subjects[84]
2019Systematic review and meta-analysis13 studies comprising 5169 CKD patientsserum fetuin-ACKD patients with the lowest fetuin-A levels had a 92% greater risk of all-cause mortality compared with those with the highest levels[98]
2019Cross-sectional238 CKD patients (stages 3–5)serum fetuin-AFetuin-A levels in ESRD patients were significantly lower than those from patients at stages 3 and 4 CKD; fetuin-A was negatively correlated with vascular calcification score and CIMT [97]
2020Cross-sectional43 adult patients with CKD and 43 healthy controlsplasma ADMALevels of ADMA positively correlate with CKD severity; FMD was significantly decreased in CKD patients, and negatively correlated with ADMA levels[86]
Abbreviations: ADMA, asymmetric dimethylarginine; CIMT, carotid intima-media thickness; CKD, chronic kidney disease; CRISIS, Chronic Renal Insufficiency Standards Implementation Study; CVE, cardiovascular event; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; FMD, flow-mediated dilation; RRT, renal replacement therapy; T2D, type 2 diabetes.
Table
Table 4. Research studies on biomarkers of inflammation and main outcomes in CKD patients.
Table 4. Research studies on biomarkers of inflammation and main outcomes in CKD patients.
YearStudy TypeStudy PopulationBiomarker (s)Study OutcomesReference
2016Prospective cohort746 individuals with GFR > 60mL/min/1.73 m2serum PTX3Higher PTX3 levels are associated with lower GFR and independently predict incident CKD in the elderly[121]
2016Prospective cohort3430 patients with reduced eGFR from the CRIC studyplasma IL-6, TNF-αElevated plasma levels of TNF-α were associated with rapid loss of kidney function in CKD patients[108]
2016Prospective cohort543 patients with stage 5 CKDplasma IL-6, TNF- αIL-6 and TNF-a could predict all-cause mortality risk; only IL-6 could classify clinical CVD[112]
2017Prospective cohort521 adults with CKD from the C-PROBE and the SKS studiesplasma or serum GDF-15Circulating GDF-15 levels were strongly correlated with intrarenal expression of GDF15 and significantly associated with increased risk of CKD progression[124]
2017Prospective cohort984 CKD patients stages 1–5serum TNFR1, TNFR2TNFR1 and 2 were associated with CVD and other risk factors in CKD, independently of eGFR[117]
2017Cross-sectional1816 community residents randomly selected from the Dong-gu studyplasma PTX3A significantly higher risk of CKD was found in the group with the highest plasma levels of PTX3 when compared to the group with the lowest levels[136]
2017Prospective cohort78 stage 5 CKD patients (51 on hemodialysis and 27 on pre-dialysis)serum PTX3,
IL-6, CRP		In contrast to CRP levels, baseline PTX3 levels predicted CV mortality independently of classic CV risk factors; PTX3 levels also significantly predicted mortality[123]
2017Prospective cohort39 ESRD patients under HD and 15 healthy controlsserum cfDNAESRD patients had a significantly higher value when compared to controls; cfDNA correlated positively with CRP levels in ESRD patients[132]
2018Prospective cohort883 adults at any stage CKD from the SKS or the C-PROBE studiesserum
GDF-15		Adults with CKD and higher circulating levels of GDF-15 presented greater mortality; elevated GDF-15 was also associated with an increased rate of HF[126]
2018Prospective cohort200 patients with T2Dplasma GDF-15Higher GDF-15 improved risk prediction of decline in kidney function; in patients with T2D and microalbuminuria, higher GDF-15 was independently associated with all-cause mortality [137]
2018Cross-sectional201 patients with CKD and 201 controls plasma PTX3Plasma PTX3 levels were increased in patients with CKD when compared to controls[138]
2019Prospective cohort3664 participants with CKD from the CRIC studyplasma GDF-15GDF-15 was significantly associated with an increased risk of CKD progression[125]
2019Prospective cohort57 CKD patients at stages 3–5 and 19 healthy controlsserum IL-6, TNF- αTNF and IL-6 were significantly higher in more advanced CKD stages; IL-6, but not TNF- α, was associated with 5-year risk of all-cause mortality in CKD patients[114]
2019Prospective cohort318 ESRD patients, undergoing HD and 22 healthy controls plasma PTX3, IL-6, TNF- α, CRPWhen comparing inflammatory mediators, the increase in PTX3 levels was the only predictor of all-cause mortality in dialysis patients[122]
2019Prospective cohort124 patients with CKD (stages 1–5)plasma and urinary cfDNANo correlations were found between cfDNA levels and CKD staging; higher urinary levels of cfDNA were associated with worse renal outcomes at 6 months[133]
2020Cross-sectional219 adult CKD patients (stages 2–5) from the GCKD studyplasma GDF-15GDF-15 was significantly elevated in CKD patients and showed a significant inverse correlation with eGFR[127]
2020Cross-sectional117 T2D patients and 11 healthy controlsserum and urinary IL-8, IL-18Serum and urinary levels of IL-8 and IL-18 were positively correlated with podocyte damage, peritubular dysfunction, and albuminuria, and negatively correlated with eGFR[115]
2020Prospective cohort2428 SPRINT participants with CKDurinary IL-18Urinary IL-18 was associated with eGFR decline and may help to detect subtle changes in eGFR[116]
2020Prospective cohort160 patients with DNserum cfDNASerum cfDNA levels were significantly negatively associated with the eGFR changes during the follow-up[134]
Abbreviations: CKD, chronic kidney disease; C-PROBE, Clinical Phenotyping and Resource Biobank Study; CRIC, Chronic Renal Insufficiency Cohort; CRP, C-reactive protein; CVD, cardiovascular disease; DN, diabetic nephropathy; eGFR, estimated glomerular filtration rate; GCKD, German Chronic Kidney Disease; GDF-15, growth differentiation factor-15; HD, hemodialysis; HF, heart failure; IL-6, interleukin-6; IL-8, interleukin-8; IL-18, interleukin-18; PTX3, pentraxin-3; SKS, Seattle Kidney Study; SPRINT, Systolic Blood Pressure Intervention Trial; T2D, type 2 diabetes; TNF-α, tumor necrosis factor alfa; TNFR, tumor necrosis factor receptor.
Table
Table 5. Research studies on metabolomics and main outcomes, in CKD patients.
Table 5. Research studies on metabolomics and main outcomes, in CKD patients.
YearStudy TypeStudy PopulationStudy OutcomesReference
2016Cross-sectional27 patients with CKD at stages 3–5Kidney function decline was associated with an increase in the inflammation marker neopterin and the metabolism of tryptophan via the kynurenine pathway[156]
2016Prospective cohort118 patients with CKD at stages 3–5 Sixteen metabolites, from variable metabolic pathways, were related to higher risk of kidney function deterioration in advanced CKD patients[157]
2016Case–control200 patients with rapid renal disease progression and 200 stable controlsTen metabolites were associated with CKD progression; six (uric acid, glucuronate, 4-hydroxymandelate, 3-methyladipate/pimelate, cytosine, and homogentisate) were higher in cases than controls, whereas four (threonine, methionine, phenylalanine, and arginine) were lower [158]
2016Prospective cohort1735 participants in the KORA F4 studySix metabolites (N-acetylalanine, N-acetylcarnosine, C-mannosyltryptophan, erythronate, pseudouridine, and O-sulfo-L-tyrosine) were associated with eGFR and CKD in both studies and showed high correlation with established kidney function markers[159]
1164 individuals in the TwinsUK registry
2016Cross-sectional291 pre-dialysis CKD patients and 56 healthy controlsThe presence of diabetes affects the metabolic phenotypes of CKD patients at an early stage, and those differences are attenuated with CKD progression[139]
2017Case–control193 patients with incident CKD from the Framingham Study and 193 matched controlsLower urinary levels of glycine and histidine were associated with a higher risk of incident CKD; moreover, the authors identified several novel associations with urinary metabolites and genetic variations[140]
2017Cross-sectional60 T2D patients with all stages of CKD from the FIND studyTryptophan levels were inversely correlated with CKD staging, while its metabolites were positively associated with the severity of kidney disease; kynurenine was positively correlated with TNF-a levels[144]
2017Cross-sectional589 CKD patients from the MDRD studyFive metabolite associations (kynurenate, homovanillate sulfate, hippurate, N2,N2-dimethylguanosine, and 16-hydroxypalmitate) showed consistently higher levels in ADPKD compared with glomerular disease and CKD of other causes[147]
2017Cross-sectional22 non-diabetic CKD stage 3–4 patients and 10 healthy controlsUrinary levels of 27 metabolites and plasma concentration of 33 metabolites differed significantly in CKD patients compared to controls; the citric acid cycle pathway was the most affected, with reduced urinary excretion of citrate, cis-aconitate, isocitrate, 2-oxoglutarate and succinate[150]
2017Cross-sectional20 CKD patients at stage 3 and 20 at stage 5, and 20 healthy controlsGlycoursodeoxycholic acid and 2-hydroxyethane sulfonate were downregulated in the urine of patients, and pregnenolone sulfate was also found to be decreased in plasma when compared to controls[160]
2018Prospective cohort56 Brazilian macroalbuminuric CKD patientsLower levels of 1,5-AG, norvaline and l-aspartic acid were significantly associated with the risk of a combined outcome of mortality, dialysis need or creatinine doubling[148]
2018Retrospective cohort227 patients with CKD and a nested subgroup of 57 for follow upEleven metabolites from various metabolic pathways were associated with reduced eGFR; increased urinary concentrations of betaine and myo-inositol were found to be prognostic markers of CKD progression[161]
2018Prospective cohort299 CKD patients from the MDRD study and 963 from the AASK cohortSerum metabolites fumarate, allantoin, and ribonate were associated with a higher risk of mortality in two cohorts of patients with CKD[146]
2018Prospective cohort1765 Chinese adults with eGFR ≥ 60 mL/min per 1.73 m2Elevated plasma levels of cysteine and several acylcarnitines were associated with eGFR reduction, independent of baseline eGFR and other conventional risk factors[162]
2019Cross-sectional587 adults with all stages of CKD and 116 healthy controlsFive serum metabolites (5-MTP, canavaninosuccinate, acetylcarnitine, tiglylcarnitine and taurine) were identified to estimate kidney filtration and enhance earlier CKD prediction[141]
2019Prospective cohort1582 participants from the AASK and MDRD studiesThe serum metabolites 4-hydroxychlorthalonil and 1,5-AG and the phosphatidylethanolamine metabolic pathway were strongly associated with proteinuria in CKD[149]
2019Cross-sectional30 patients with CKD at stages 3 and 4 and 30 healthy volunteersMore significant changes in acylcarnitines, carbohydrates (such as glucose and myo-inositol), and glycerophospholipid metabolism pathways were found in CKD patients than in controls[163]
2019Retrospective cohort214 CKD patients from the CPROBE and 200 from the CRIC studiesIn CKD patients, changes in the triacylglycerols and cardiolipins-phosphatidylethanolamines preceded the clinical outcomes of ESRD by several years[145]
2019Cross-sectional1243 participants from the BHS and 260 from the MESA studies This study identified 39 novel metabolites in sub-pathways previously associated with kidney function, and 12 novel metabolites in sub-pathways with novel associations[164]
2019Retrospective cohort454 patients with CKD at stages 3 and 4 from the Progredir Cohort StudyD-malic acid, acetohydroxamic acid, butanoic acid, ribose, glutamine, trans-aconitic acid, lactose and an unidentified molecule (m/z 273) were positively related to the risk of overall mortality, while docosahexaenoic acid was inversely related to this risk; lactose, 2-O-glycerol-α-d-galactopyranoside, and tyrosine were associated with ESRD progression[165]
2019Cross-sectional140 CKD patients and 144 healthy subjectsCKD patients presented significantly lower serum levels of 3-indolepropionic acid and higher serum levels of indoxyl sulfate and p-cresol sulfate when compared to controls[166]
2020Prospective cohort1741 subjects from the Ansan-Ansung population studyResearchers found 22 metabolites associated with eGFR and CKD prevalence; citrulline, kynurenine, and the kynurenine/tryptophan ratio were associated with incident CKD[142]
2020Prospective cohort184 patients with CKD at stages 1–5 from the CPROBE studyKynurenic acid, 3-hydroxykynurenine and kynurenine were increased with CKD stage progression; higher tryptophan levels at baseline were associated with lower odds of incident CVD[143]
2020Prospective cohort501 patients with ADPKD, with different stages of CKDFour urinary metabolites (myo-inositol, 3-hydroxyisovalerate, ADMA and creatinine) were strongly associated with baseline eGFR; the urinary alanine/citrate ratio showed the best association with eGFR decline[167]
Abbreviations: 1,5-AG, 1,5-anhydroglucitol; 5-MTP, 5-methoxytryptophan; AASK, African American Study of Kidney Disease and Hypertension; ADMA, asymmetric dimethylarginine; ADPKD, autosomal dominant polycystic kidney disease; BHS, Bogalusa Heart Study; CKD, chronic kidney disease; CPROBE, Clinical Phenotyping Resource and Biobank Core; CRIC, Chronic Renal Insufficiency Cohort Study; CVD, cardiovascular disease; DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; FIND, Family Investigation of Nephropathy in Diabetes; KORA, Cooperative Health Research in the region of Augsburg; MDRD, Modification of Diet in Renal Disease; MESA, Multi-Ethnic Study of Atherosclerosis; T2D, type 2 diabetes; TNF-α, tumor necrosis factor alph
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lousa, I.; Reis, F.; Beirão, I.; Alves, R.; Belo, L.; Santos-Silva, A. New Potential Biomarkers for Chronic Kidney Disease Management—A Review of the Literature. Int. J. Mol. Sci. 2021, 22, 43. https://doi.org/10.3390/ijms22010043

AMA Style

Lousa I, Reis F, Beirão I, Alves R, Belo L, Santos-Silva A. New Potential Biomarkers for Chronic Kidney Disease Management—A Review of the Literature. International Journal of Molecular Sciences. 2021; 22(1):43. https://doi.org/10.3390/ijms22010043

Chicago/Turabian Style

Lousa, Irina, Flávio Reis, Idalina Beirão, Rui Alves, Luís Belo, and Alice Santos-Silva. 2021. "New Potential Biomarkers for Chronic Kidney Disease Management—A Review of the Literature" International Journal of Molecular Sciences 22, no. 1: 43. https://doi.org/10.3390/ijms22010043

APA Style

Lousa, I., Reis, F., Beirão, I., Alves, R., Belo, L., & Santos-Silva, A. (2021). New Potential Biomarkers for Chronic Kidney Disease Management—A Review of the Literature. International Journal of Molecular Sciences, 22(1), 43. https://doi.org/10.3390/ijms22010043

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop